ID,PAPER_TYPE,CHEMICAL,CHEMICAL_FAMILY,NAME,ASSAY_ENDPOINT_DESCRIPTION,ASSAY_COMPONENT_NAME,ASSAY_COMPONENT_DESCRIPTION,DESCRIPTION,SEQAPASS,GENE_SYMBOL,GENE_URL,GENE_NAME,AOP,EVENT,HIT_CALL,CONTINUOUS_HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,CUTOFF,ACC,AC10,BMR,BMD,BMAD,MAX_MED_CONC,NORMALIZED_DATA_TYPE,ASSAY_SOURCE,ASSAY_NAME,ASSAY_DESC,ASSAY_FUNCTION_TYPE,FLAGS,STOCK_CONC,STOCK_CONC_UNITS,ORGANISM,CELL_LINE,CELL_FORMAT,CONCENTRATION,RESPONSE,CYTOTOX_BURST,INTENDED_TARGET_FAMILY,INTENDED_TARGET_TYPE,INTENDED_TARGET_TYPE_SUB,INTENDED_TARGET_FAMILY_SUB,BIOLOGICAL_PROCESS_TARGET,DETECTION_TECHNOLOGY_TYPE,TISSUE,SAMPLE_ID,REPR,DOI,TOXICITY_DOMAIN,REFERENCE,URL_COMPTOX
1,PARC,Deltamethrin,Pyrethroid,hNNF assay (hiPSC-derived neural network formation),"Effects of deltamethrin on neural network formation and function in human iPSC-derived co-cultures measured by network burst, spike, and connectivity parameters using multi-electrode arrays (MEA); calculation of BMCs for sensitive endpoints","Hnnf (human neural network formation and function) – number of spikes per network burst (MSE), plus other network parameters","Chronic exposure of human iPSC-derived neuron:astrocyte (52:22:26%) networks to deltamethrin (0.027–20µM) 1/week, 5 time points, assessment of spontaneous neural activity and cytotoxicity","Investigation of deltamethrin-induced perturbation of human neural network development and activity, using hNNF MEA assay, including time/concentration response, area under curve, and benchmark concentration analysis",-,-,-,-,Voltage-gated sodium channel modulation (MIE in EFSA DNT AOP for deltamethrin) → altered network function → behavioral impairment”  (Figure 7),Most sensitive: reduction in “number of spikes per network burst”; inhibition of network activity (molecular initiating event: voltage-gated sodium channel interference),Positive” if ≥1 network parameter affected (BMC50) without cytotoxicity; deltamethrin positive in ≥5 parameters,-,-,-,-,-,BMC calculation; 50% benchmark response (BMR50: 50% change from control baseline),-,-,"50% (BMR50 for reduction, BMR50ind for induction of effect)","BMC50 (most sensitive endpoint): 2.74µM (hNNF, “number of spikes per network burst”)",-,20µM (hno overt cytotoxicity in positive parameters),Electrophysiological readings normalized to control; area under curve (AUC) and BMC modeling,"IUF-Leibniz Research Institute for Environmental Medicine, NeuCyte Inc., DNTOX GmbH",Human neural network formation (hNNF) MEA assa,"Deltamethrin exposure of hiPSC-derived neuron/astrocyte co-cultures, 35 days on MEA, functional and cytotoxicity endpoints measured weekly, BMC analysis for network parameters","Functional neural network activity/profiling (electrophysiology, neurotoxicity)","Positive control (Bis-I), negative control (acetaminophen); assignment of “positive” if BMC50 for network parameter without cytotoxicity",20,mM,human,"iPSC-derived excitatory/inhibitory neurons (SynFire), and primary human astroglia","co-culture (52% glutamatergic neurons, 22% GABAergic neurons, 26% astrocytes)","0.027, 0.082, 0.247, 0.74, 2.22, 6.67, 20 µM","Concentration-dependent reduction in network parameters (5/14 affected, most sensitive: “spikes per network burst”, BMC50: 2.74µM)",No cytotoxicity at active concentrations,Voltage-gated sodium channels; neuronal and synaptic networks,Ion channel modulator (Sodium channel blocker/disrupter); developmental neurotoxicity,Voltage-gated sodium channel subtypes,-,"Neural network formation, synaptic activity, neuronal firing/bursting, network connectivity/organization","Multi-electrode array (MEA), electrical activity recording","In vitro model of developing human brain (neuronal/glial co-culture, hiPSC-derived)",-,"2–3 independent experiments per compound, 3 technical replicates each",doi:10.14573/altex.2206031  ,Developmental neurotoxicity (DNT),-,-
2,PARC,Deltamethrin,Pyrethroid,Neurosphere Assay (NPC5),"Impact of deltamethrin on oligodendrocyte differentiation (NPC5 assay) in human neurosphere cultures. 	Neurosphere Assay (NPC5): evaluates effects of compounds  on human OL differentiation and viability to determine developmental neurotoxicity; measures % of O4-positive cells and cytotoxicity (mitochondrial activity); dose-response analysis.",Neurosphere Assay (NPC5),"Primary hNPCs isolated from fetal cortex (Lonza), cultured as neurospheres, differentiated for 5 days on PDL-laminin plates, assessed for oligodendrocyte lineage markers (O4) and nucleus (Hoechst); %O4+ cells, cell viability.",-,-,"MBP (myelin basic protein), PDGFRA, CNP, GALC, PLP1 (oligodendrocyte lineage markers for validation; assay endpoint uses O4 immunostaining).",-,"Myelin basic protein, Platelet-derived growth factor receptor alpha, 2',3'-cyclic nucleotide 3' phosphodiesterase, Galactosylceramidase, Proteolipid protein 1","
Disrupted oligodendrocyte differentiation leading to myelination deficits and neurodevelopmental dysfunction.","
Decreased (inhibited) oligodendrocyte differentiation (↓% O4+ cells); impaired neurodevelopmental key event.",Active,-,-,-,-,-,-,-,-,-,-,-,20 μM,%O4+ cells normalized to solvent (control); viability (mitochondrial activity) normalized to solvent control.,"IUF—Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany","NPC5 (Oligodendrocyte differentiation), Neurosphere Assay",NPC5: Differentiation of human neurospheres for 5 days in presence of deltamethrin (various concentrations); assessed for %O4+ oligodendrocytes via immunostaining and cell viability (mitochondrial activity).,"
Phenotypic, mechanistic, developmental neurotoxicity, cell-type specific differentiation assay.",-,20,mM,human,"hNPCs, neurospheres (Lonza)",cell line,"0.027, 0.2, 1, 5, 10, 20 μM",Dose-dependent decrease in %O4+ oligodendrocytes (impaired differentiation); mitochondrial activity also shows cytotoxicity at higher doses ,Assessed via cell viability (mitochondrial activity); high doses also decrease viability.,"Ion channels (voltage-gated sodium channels in general mode-of-action), OL differentiation process","Oligodendrocyte, neural progenitor, myelin","O4+ oligodendrocyte markers, MBP transcription in validation.",-,"Oligodendrocyte differentiation, myelination, neuronal development",,brain,-,n ≥3 independent replicates for assays,10.3389/ftox.2022.816370,Developmental neurotoxicity (DNT),-,-
3,BioStudies,Deltamethrin,Pyrethroid,MEA on primary rat cortical neurons,"Effects on spontaneous network activity (mean firing rate, burst rate, synchrony) of primary rat cortical neurons grown on multi-electrode arrays (MEA) in vitro.",MEA of primary rat cortical neurons,"Dissociated postnatal day 0–1 rat cortical neurons cultured on glass MEA platforms, allowed to mature until DIV 13–30, form synaptically connected networks.","In vitro neurotoxicity screening using MEAs: quantifying the impact of deltamethrin on cortical neuronal network activity (spiking, bursting, synchrony).",-,-,-,-,modulation of voltage-gated sodium channels,Decreased mean firing rate and network synchrony in cultured cortical neurons following deltamethrin exposure.,Active,-,-,-,0.19 μM (EC50 for mean firing rate reduction),-,-,-,-,-,-,-,not specified,"Activity expressed as percentage of control (baseline), mean ± SEM over recordings; data normalized to baseline per MEA.","US EPA (ORD, NHEERL)",Microelectrode array-based neural network function assay (neuronal network electrophysiology),"Recording of spike and burst parameters (MFR, burst rate, % of active electrodes, synchrony) before and after cumulative dosing with test compounds.",Neuronal network function/toxicity screen,-,-,-,rat,Primary cortical neurons,monolayer on MEA,"Cumulative, typically from 1pM to 100μM;",Marked decrease in mean firing rate and synchronous network bursting; EC50=0.19μM for firing rate reduction; network synchrony at 0.3μM: 24.7% of control ,not assayed,Voltage-gated sodium channels ,Neuronal ion channel,"
Sodium channel",Neuronal channels associated with action potential initiation,"Neuronal excitability, spontaneous network activity, synaptic transmission",Microelectrode array electrophysiology,brain,-, multiple networks/MEA chips across independent cultures (N=10 for deltamethrin),https://doi.org/10.1016/j.neuro.2013.11.008,NT,-,-
4,BioStudies,Deltamethrin,Pyrethroid,wMFR and AEs on primary rat cortical neurons,Effects of deltamethrin exposure on mean firing rate (wMFR) and number of active electrodes (AEs) in primary rat cortical neuron networks on multi-well microelectrode arrays (mwMEA), and AEs on primary rat cortical neurons,"Postnatal day 0–1 (P0–P1) Long-Evans rat cortical neurons dissociated, plated on 12-well MEA plates (64 electrodes per well), cultured for DIV 14–22 before testing",High-throughput screening for neurotoxic/neuroactive compounds using spontaneous network activity in rat cortical cultures on mwMEAs,-,-,-,-,Disruption/modulation of voltage-gated sodium channel (VGSC) gating in neurons (pyrethroid mode of action),Increased weighted mean firing rate (wMFR) (+24.6%); decreased number of active electrodes (AEs) (–33.5%); changes in network excitability,Active,-,-,-,-,-,"
14% change in wMFR; 20% change in # active electrodes (AEs)",-,-,-,-,-,50 μM,"wMFR (spikes/min, weighted by number of active electrodes), percent of control","Multi-well MEA platform (Axion Biosystems/AxIS), EPA Integrated Systems Toxicology Division",Multi-well microelectrode array spontaneous network activity assay,"Recordings of spontaneous activity before and after deltamethrin application, quantifying changes in network spike rate and AEs",Neuronal network function/toxicity screen,-,50,mM,rat,Primary cortical neurons,monolayer on MEA,,Mean wMFR increased by +24.6%; number of active electrodes (AEs) decreased by –33.5% compared to baseline,No cytotoxicity at 50  μM,Voltage-gated sodium channels ,Neuronal ion channel,"
Sodium channel",-,"Neuronal excitability, action potential generation, synaptic transmission",Microelectrode array electrophysiology,brain ,-,3–7 replicates,https://doi.org/10.1016/j.neuro.2012.05.001,NT,-,-
5,BioStudies,Deltamethrin,Pyrethroid, Neural network development; identification of toxicological tipping points where network recovery fails.,"9 primary network activity parameters: mean firing rate (MFR), number of active electrodes (#AE), burst rate (BR), number of actively bursting electrodes (#ABE), percent of spikes in bursts (%SiB), number of network spikes (#NS), percent of spikes in network spikes (%SiNS), Pearson correlation (r), mutual information (MI)", Neural network development; identification of toxicological tipping points where network recovery fails.,"Parameters reflect spontaneous spiking, bursting, synchrony, and connectivity in developing networks recorded using MEAs.",-,-,-,-,-,network function disruption as an early key event for developmental neurotoxicity (DNT),Disruption of spontaneous neural network formation and function during early in vitro development,Active,-,-,-,-,-,-,-,-,-,-,-,30μM ,"Z-scored, plate-normalized fold-change vs. controls for each network paramete",US EPA Integrated Systems Toxicology Division,Microelectrode Array Neural Network Development Assay (mwMEA),Medium-throughput assay quantifying disruption of network development in primary rat cortical cultures by monitoring electrical activity over 12 days in vitro,"Functional, physiological neurotoxicity screening",-,-,-,rat,Primary mixed cortical neuron culture,primary culture,"Critical concentration (tipping point): 0.05 µM (DIV5 to DIV12), 95% CI: 0.036–0.145 µM",Demonstrated concentration-dependent perturbation resulting in irreversible functional impairment of neural network formation,Tipping point below cytotoxic concentration thresholds—functional effects precede cell viability loss,"Nervous system related targets (likely ion channel modulators, consistent with pyrethroid MoA)",Voltage-gated sodium channel modulator ,-,-,Neural network formation; developmental neurotoxicity screening,Microelectrode array (MEA) extracellular electrophysiology,brain,-,-,https://doi.org/10.1016/j.taap.2018.01.017,DNT,-,-
6,Lit_review,Deltamethrin,Pyrethroid, Colony Forming Ability (CFA) assay,"in vitro technique to assess the long-term survival, proliferation, and cytotoxic effects of chemical treatments on cells. The assay measures the ability of a single viable cell to undergo unlimited division and form a colony consisting of at least 50 cells. This ability reflects the reproductive viability and proliferative capacity of the cells following exposure to a test compound.",-,-,-,-,-,-,-,-,cell cycle arrest,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,colony forming ability (CFA) assay + cell cycle analysis by flow cytometry + microscopic evaluation of the mitotic index.,"CFA assay is a widely used in vitro technique to assess the long-term survival, proliferation, and cytotoxic effects of chemical treatments on cells. The assay measures the ability of a single viable cell to undergo unlimited division and form a colony consisting of at least 50 cells. This ability reflects the reproductive viability and proliferative capacity of the cells following exposure to a test compound.",viability ,-,-,-,hamster,V79,cell line ,3.1–100 mg/ml,"The colony forming ability (CFA) resulted in distinct differences of the cytotoxic effect of the tested pyrethroids, whereby permethrin was found to be most toxic. With the exception of fenvalerate all tested pyrethroids gave rise to inhibition of cell cycle progression as shown by G2/M-arrest of synchronized V79 cells by flow cytometry as well as by the increase of the mitotic index as evaluated by light microscopy. ",-,-,-,-,cytotoxicity,cell cycle,Fllow-cytometry and microscopy,lung,-,-,https://doi.org/10.1016/S0378-4274(99)00034-X,-,-,-
7,Lit_review,Deltamethrin,Pyrethroid,MTT and LDH release assays,MTT assay to assess cell viability/cytotoxicity and LDH release assay for membrane integrity. Confocal and light microscopy used for morphological assessment.,-,-,-,-,-,-,-,-,cytotoxicity ,Active,-,-,-, 38.2 ng/mL,-,-,-,-,-,-,-,200 ng/mL ,-,-,"MTT assay, LDH release, EROD activity (CYP1A), microscopy",MTT: Mitochondrial function and cell viability. LDH: Membrane damage/cell lysis during apoptosis/necrosis. EROD: Measurement of CYP1A induction indicating biotransformation/phase I metabolic capacity. Microscopy: Morphological characterization of cellular/subcellular alterations,"viability, cytotoxicity, and enzyme induction",-,10,mg/mL,trout,RTG-2,cell line ," 6.25, 12.5, 25, 50, 100, 200 ng/mL for toxicity assays; IC50 for microscopy/EROD (105.3 ng/mL)","IC50 (MTT assay): 38.2 ng/mL (MTT endpoint, 24-hour exposure). LDH leakage (membrane integrity): Peak value 74.48 ± 19.90% at all treated doses; not clearly dose-dependent. EROD (CYP1A activity): 33.78 ± 0.28 pmol/min/mg protein at IC50; fold increase over control: 5.29 ± 0.04. Morphological effects (microscopy): Fragmented cytoskeleton, pyknotic/condensed nuclei, hole formation, micronucleus formation, cell shrinkage, vacuolization, hydropic degeneration.",-,-,-,-,-,-,Colorimetric (MTT/LDH); Fluorometric (EROD); Microscopy,Gonadal/mixed testis-ovary cells,-,-,https://doi.org/10.1080/15569543.2017.1366922,-,-,-
8,Lit_review,Deltamethrin,Pyrethroid,Genotixicity and chromosomal damage with the cytokinesis-block method to assess micronulie formation after exposure to pyrethroids,"The cytokinesis-block method with 6 μg/ml cytochalasin B (Cyt-B) is a widely used technique in the cytokinesis-block micronucleus (CBMN) assay to assess chromosomal damage and genotoxicity. Cytochalasin B is a drug that inhibits actin polymerization, specifically blocking the formation of the contractile ring required for cytokinesis (the final step of cell division where the cytoplasm divides). By adding Cyt-B to cultured cells at a concentration of about 6 μg/ml, cytokinesis is prevented while nuclear division proceeds normally, resulting in the accumulation of binucleated cells, i.e., cells with two nuclei.",-,,-,-,-,-,-,-,micronucleus formation (MN) and cytotoxicity,Active,-,-,-,-,-,-,-,-,-,-,-,200  μg/mL,-,-,cytokinesis-block micronucleus (CBMN) assay,"It is a well-established cytogenetic assay that detects chromosomal damage by scoring micronuclei in binucleated cells, providing sensitive measurement of genetic damage caused by chemical agents such as insecticides in human lymphocyte cultures",viability ,-,-,-,human ,whole blood and lymfocytes,peripheral blood lymphocytes ,10-200  μg/mL,"At the concentration ranges tested, all the five pyrethroids induced clear dose dependent cytotoxic effects, fenpropathrin being the most toxic. Nuclear division index (NDI) and the newly introduced index of cytotoxicity, the cytokinesis block proliferation index (CBPI), reflected the dose dependency more accurately than the percentage of binucleated cells did.",-,-,-,-,cytotoxicity,cell cycle/proliferation,Fluorescence,blood,-,-, 10.1016/0165-1218(95)90007-1,-,-,-
9,Lit_review,Deltamethrin,Pyrethroid,Cytotoxicity assessed by cell viability; protective efficacy against pyrethroid cytotoxicity,MTT cytotoxicity assay measuring cell viability after exposure to insecticides including permethrin; enzymatic assays for P450 detoxification activity on Sf9 insect cells engineered to express mosquito P450 enzymes CYP6P7 or CYP6AA3. They were used to test detoxification capacity.,-,-,-,-,"CYP6P7, CYP6AA3",-,Cytochrome P450 monooxygenases CYP6P7 and CYP6AA3,Detoxification of permethrin by cytochrome P450 enzymes reduces cytotoxicity; inhibition of P450 increases cytotoxicity,"Cytoprotection from cytotoxicity, enzymatic metabolism of permethrin",Active,-,-,-,-,-,-,-,-,-,-,-,500 µM,Cell viability percentage,-,"MTT cytotoxicity assay, in vitro enzymatic reconstitution assay",Measurement of cytotoxicity and detoxification enzyme activity against permethrin in Sf9 insect cells,"viability, detoxification capability assessment",-,-,-,Spodoptera frugiperda,Sf9 ,cell line ,0.1-500 µM x 72h," The results revealed that CYP6P7- or CYP6AA3-expressing cells showed significantly higher cytoprotective capability than parental Sf9 cells against cytotoxicity of pyrethroids including permethrin, cypermethrin and deltamethrin. Such cytoprotective effect was not observed for chlorpyrifos. Moreover, expression of CYP6AA3, but not CYP6P7, could protect cells against λ-cyhalothrin cytotoxicity. In MTT assays upon co-incubation with piperonyl butoxide (P450 inhibitor), cytoprotective ability of CYP6P7 and CYP6AA3 against deltamethrin was diminished, implying that pyrethroid detoxification was due to activities of P450 enzymes. ",-,Cytochrome P450 enzymes,Enzymes,Monooxygenases,cytotoxicity,"Xenobiotic metabolism, detoxification",Colorimetric MTT assay,insect cells,-,-,https://pubmed.ncbi.nlm.nih.gov/22041748/,-,-,-
10,Lit_review,Deltamethrin,Pyrethroid,"Inhibition of housefly-head acetylcholinesterase (AChE) activity, measured by reduction in enzymatic activity",Acetylcholinesterase inhibition bioassay,-,-,-,-,-,-,-,-,AChE activity inhibition,Active (mixture of substances),-,-,-,-,-,-,-,-,-,-,-,10 mg/L fixed as maximum cypermethrin concentration used in mixtures; not tested as single substance,-,-,Housefly-head AChE in vitro inhibition assay,Microplate-based assay measuring residual AChE activity after 10-min pesticide exposure using DTNB/ATCh read at 405 nm,"
Functional enzyme inhibition",,4–5,g/L,housefly,purified tissue from head,cell lisate,0.1 mg/L and 10 mg/L in binary combinations with OP/CB pesticides,"Synergistic increase in AChE inhibition potency of OP/CB partners, especially for chlorpyrifos (CPF), triazophos (TRZ), malathion (MLT)",-,Enzyme (hydrolase),Acetylcholinesterase inhibitor ,-,-,synaptic function/neurotransmission,Colorimetric enzyme assay,insect head extract,-,3 experiments × 3 replicates,10.1016/j.toxlet.2016.12.009,-,-,-
11,Lit_review,Deltamethrin,Pyrethroid,Changes in sodium current parameters in mammalian neuronal membrane,"Changes in sodium channel gating, amplitude and kinetics in response to deltamethrin in mouse neuroblastoma cells (N1E-115) using voltage clamp",-,-,-,-,-,-,-,Voltage-gated sodium channel modulation,"
Increased sodium current amplitude, slowed decay during depolarization, pronounced slow tail sodium current",Active,-,-,-,-,-,-,-,-,-,-,-,100 μM ,-,-,Voltage clamp sodium current assay,"Measurement of sodium currents in N1E-115 neuroblastoma cells after deltamethrin exposure, including peak, decay, tail current, and voltage dependency",Electrophysiological functional assay ,-,-,-,mice,N1E-115,cell line , 100 μM ,"Marked slowing of sodium current decay, very large and slowly decaying sodium tail current after repolarization, increased sodium influx, no effect on inactivation or recovery from inactivation",-,Voltage-gated sodium channels (Nav),Ion channel protein,-,-,"Neuronal excitability, action potential generation",Whole-cell voltage clamp electrophysiology,brain ,-,-,https://doi.org/10.1016/0006-8993(87)91645-3,-,-,-
12,Lit_review,Deltamethrin,Pyrethroid,Yeast survival rate and frequency of ρ-mutation,Yeast survival rate and frequency of ρ-mutation (mitochondrial DNA deletion mutants) after deltamethrin exposure,-,-,-,-,-,-,-,oxidative stress leading to mitochondrial DNA mutation,Reduced yeast cell survival; increased ρ-mutation frequency,Active,-,-,-,"
~20 μg·cm⁻³ for 50% cell death at logarithmic growth; ~80 μg·cm⁻³ for stationary phase",-,-,-,-,-,-,-,60 μg·cm⁻³ for log phase (0% survival at ≥40 μg·cm⁻³); 200 μg·cm⁻³ for stationary phase (0% survival at ≥140 μg·cm⁻³),-,-,Yeast survival and petite (ρ-) mutant frequency assay,"Yeast cultures exposed to deltamethrin at various concentrations; survival assessed by colony formation, ρ-mutation by inability to grow on non-fermentable carbon sources",Cytotoxicity and mitochondrial mutagenicity ,-,-,-,"
Saccharomyces cerevisiae (yeast)",SP4 – Mat alpha leu1 arg4 (wild-type laboratory yeast strain),cell culture,"0, 5, 10, 15, 20, 25, 30, 40, 50, 60 μg·cm⁻³ for log phase. Up to 200 μg·cm⁻³ for stationary phase","Deltamethrin most toxic: causes rapid drop in survival and dramatic increase in ρ-mutants at low concentrations. At 20 μg/cm³, 50% loss of viability in log phase, 38% ρ-mutants among survivors.",-,Mitochondria,Organelle; mitochondrial DNA,"
mtDNA mutation (ρ-mutation/petite mutation)",-,Mitochondrial DNA maintenance; cell survival; oxidative phosphorylation,"Colony formation assay, phenotypic screen for petites (growth on non-fermentable media)",Whole yeast cell,-,-,"https://www.pjoes.com/The-Influence-of-Selected-Pyrethroid-on-the-Growth-r-nand-Number-of-Mutants-in-Saccharomyces,88002,0,2.html",-,-,-
13,Lit_review,Deltamethrin,Pyrethroid,"Cell proliferation, cellular uptake and localization of deltamethrin in animal fibroblasts and plant (algal) cells","Inhibition of cell proliferation, cellular uptake and localization of deltamethrin in animal fibroblasts and plant (algal) cells; flow cytometric analysis of cell cycle",-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,"
5 × 10⁻⁴ M (pure deltamethrin for fibroblasts and algae); higher than environmental, near saturation",-,-,Cell proliferation inhibition and cellular uptake assays; autoradiography for localization; flow cytometry for cell cycle analysis,Cell numbers counted after exposure; [³H]deltamethrin uptake measured by scintillation; autoradiograms for subcellular localization; cell cycle phases by flow cytometry,"Cytotoxicity, cell binding, and cell cycle analysis assays",-,-,-,"Animal: mice; Plant: Dunaliella bioculata (marine microalga), Chlamydomonas reinhardii (green algae)","Mouse fibroblast NCTC clone L 929; D. bioculata, C. reinhardii (lab strains)",cell culture,"pure deltamethrin: 5 × 10⁻⁵ M to 5 × 10⁻⁴ M; DECIS EC (commercial formulation): 9 × 10⁻⁷ M and above; DECIS FLO (commercial formulation): up to 2 × 10⁻⁴ M (algae), 5 × 10⁻⁴ M (fibroblasts)","Pure deltamethrin slowed fibroblast growth, not algal; commercial formulations more cytotoxic (cell death at lower concentrations)",-,-,-,-,-,"Cell proliferation, cellular uptake/retention, cell cycle","Cell counts, flow cytometry, liquid scintillation counting, autoradiography",fibroblasts; unicellular algae,-,-,https://doi.org/10.1016/0048-3575(87)90118-0,-,-,-
14,Lit_review,Deltamethrin,Pyrethroid,Modulation of voltage-gated Na+ channels,"Modulation of voltage-gated Na+ channels (after-potential amplitude, depolarization, and Na+ influx) in insect axons and mammalian neuronal cells",-,-,-,-,-,-,-,-,"Increased after-potential amplitude, slow depolarization leading to inexcitability in neurons, massive Na+ influx",Active,-,-,-,-,-,-,-,-,-,-,-,100 μM in mouse neuroblastoma Na+ uptake; up to 5 μM for axonal depolarization,-,-,"Electrophysiological measurement (action and after-potential in axons), 22Na+ uptake assay in cultured neuronal cells","
For axons: Resting/action potential and after-potential changes in insect nerve cord. For neuroblastoma: 22Na+ uptake reflecting channel opening",Functional (electrophysiology and radiotracer uptake for channel activity/gating),-,1 for electrophysiology; 10 for uptake assays,mM,insect; mice,Axons (isolated nerve cord prep); N1E-115,-,Axons: 0.5–5 μM (electrophysiology); Neuroblastoma: 0.5–100 μM for Na+ uptake,"In axons: rapid increase in after-potential, then slow depolarization and decreased action potential amplitude. In N1E-115: strong, concentration-dependent increase in Na+ uptake (max 22 nmol/min/mg at 100 μM)",-,Voltage-gated sodium channels (NaV),-,-,Channel gating,"Neuronal excitability, action potential generation/propagation, sodium electrochemical gradient","Intracellular electrode recording, radiotracer (22Na+) uptake measurement",brain ,-,-,https://doi.org/10.1016/0048-3575(85)90141-5,-,-,-
15,Lit_review,Deltamethrin,Pyrethroid,Neurotrophic effects on cultured rat cortical neurons,"
Neurotrophic effects of deltamethrin (DM) on cultured rat cortical neurons measured by cell survival (MTT assay), neurite complexity and length, Bdnf mRNA expression, and promoter activation.",-,-,-,-,Bdnf ,https://www.ncbi.nlm.nih.gov/gene/24225,Brain-derived neurotrophic factor,"Deltamethrin modulates voltage-sensitive sodium channels → membrane depolarization → increased Ca2+ influx via L-type voltage-dependent calcium channels (L-VDCC) → activation of Ca2+-responsive elements in Bdnf promoter → increased Bdnf expression → neurotrophic effects (neurite outgrowth, survival)",Increased neuronal survival; enhanced neurite outgrowth and complexity; elevated Bdnf mRNA expression and promoter IV activity via Ca2+-mediated signaling,Active,-,-,-,-,-,-,-,-,-,-,-,10 mM,-,-,"
Neurotrophic and transcriptional activation assays in rat cortical neuron primary culture","
MTT assay for cell viability; immunostaining and GFP reporter for neurite analysis; qRT-PCR for Bdnf mRNA; luciferase reporter assay for Bdnf promoter activation; Ca2+ imaging","Functional cellular assays including viability, morphology, gene expression, promoter activity, and intracellular Ca2+ dynamics",-,-,-,rat,Primary cortical neurons,cell culture,"0.1, 1, 10 mM deltamethrin used for survival; 1 mM primarily for neurite outgrowth and gene expression assays",Increased cell survival at 0.1 and 1 mM; no increase at 10 mM. Increased neurite complexity and length at 1 mM. Bdnf mRNA expression increased ~150x at 1 mM. Elevated intracellular Ca2+ and Bdnf promoter IV activity were observed.,-,Voltage-sensitive sodium channels (VSSC) ,-,-,-,"Neuronal survival, neurite growth, Bdnf gene transcription, intracellular calcium signaling","MTT viability assay; fluorescence microscopy (GFP, immunostaining); qRT-PCR; dual-luciferase reporter assay; fluorescence Ca2+ imaging",brain ,-,-,10.1016/j.neuropharm.2011.10.023,-,-,-
16,Lit_review,Deltamethrin,Pyrethroid,Stimulation of intracellular sodium (Na+) influx in primary cultures of cerebrocortical neurons ,Concentration-dependent stimulation of intracellular sodium (Na+) influx in primary cultures of cerebrocortical neurons by deltamethrin and other pyrethroids,-,-,-,-,-,-,-,Deltamethrin binds to voltage-gated sodium channels → shifts activation and slows inactivation → sustained increase of intracellular Na+ → neuronal excitability disturbance,Increased TTX-sensitive sodium influx in neurons observed as increased SBFI fluorescence,Active,-,-,-,-,-,-,-,-,-,-,-,30 μM,-,-,Sodium influx assay using sodium-binding fluorescent dye SBFI,"
Measurement of intracellular sodium concentration changes in mouse primary cerebrocortical neurons loaded with SBFI dye after pyrethroid exposure",Functional live-cell assay for ion channel activity,-,100,mM,mice,Primary cerebrocortical neuron culture,cell culture,0.03 nM to 30 μM,Concentration-dependent increase in Na+ influx; maximal ~27% elevation relative to control; blocked by TTX indicating VGSC mediation,-,Voltage-gated sodium channels (VGSCs),-,-,-,Neuronal excitability via modulation of Na+ channel gating,Fluorescence,brain ,-,-,https://doi.org/10.1289/ehp.1003394,-,-,-
17,Lit_review,Deltamethrin,Pyrethroid,"Gene expression of BDNF mRNA and protein levels in cultured rat cortical neurons and rat brain, neurite complexity and survival effects","Activity-dependent gene expression of brain-derived neurotrophic factor (BDNF) mRNA and protein levels in cultured rat cortical neurons and rat brain, neurite complexity and survival effects",-,-,-,-,Bdnf ,https://www.ncbi.nlm.nih.gov/gene/24225,Brain-derived neurotrophic factor,Deltamethrin prolongs opening of voltage-sensitive sodium channels → membrane depolarization → Ca2+ influx primarily via L-type voltage-dependent calcium channels (L-VDCC) → activation of ERK/MAPK signaling → increased transcription and expression of BDNF → neurotrophic effects on neurons,"
Increased BDNF exon III–V mRNA and protein expression; enhanced neurite complexity and length; increased neuronal survival from low micromolar concentrations",Active,-,-,-,-,-,-,-,-,-,-,-,10 μM,-,-,"qRT-PCR, ELISA, neurite morphology assays, promoter-luciferase assays, immunoblotting for ERK phosphorylation","
Measurement of BDNF mRNA by qRT-PCR, protein by ELISA; neurite complexity by GFP immunostaining; luciferase reporter for BDNF promoter activity; ERK1/2 phosphorylation by immunoblot","
Molecular and cellular functional assays",-,-,-,rat,Primary rat cortical neurons,cell culture,"10 nM to 10 μM, mainly 1 μM for optimal effects",Up to ~150-fold increase in BDNF mRNA (exon III–V); sustained for 72 h; increased BDNF protein; increased neurite complexity and length; increased neuronal survival; effects inhibited by TTX and Ca2+ channel blockers,-,"
Voltage-sensitive sodium channels (VSSC), L-type voltage-dependent calcium channels, MAPK signaling components","Ion channels (VSSC, L-VDCC), intracellular signaling kinases (ERK/MAPK), transcriptional regulation machinery",-,-,"
Neuronal activity, gene transcription, neuronal survival, neurite outgrowth","qRT-PCR, ELISA, fluorescence microscopy (GFP, immunostaining), luciferase reporter assay, immunoblotting, MTT cell viability assay",brain ,-,-,10.1124/jpet.105.092478,-,-,-
18,Lit_review,Deltamethrin,Pyrethroid,Induction of Bdnf exon IV-IX mRNA expression and morphological changes in cultured rat cortical neurons,Induction of brain-derived neurotrophic factor (Bdnf) exon IV-IX mRNA expression and morphological changes (neurite complexity and length) in cultured rat cortical neurons by deltamethrin and its derivatives,-,-,-,-,Bdnf ,https://www.ncbi.nlm.nih.gov/gene/24225,Brain-derived neurotrophic factor,Deltamethrin and derivatives modulate neuronal voltage-sensitive sodium channels → neuronal depolarization → Ca2+ influx via L-type Ca2+ channels → ERK/MAPK pathway activation → increased Bdnf transcription and mRNA expression → neurite outgrowth and complexity increase,Concentration-dependent increases in Bdnf eIV-IX mRNA expression; increased neurite complexity and length,Active,-,-,-,-,-,-,-,-,-,-,-,100 μM for derivatives; 1 μM for deltamethrin,-,-,"
Real-time quantitative RT-PCR for Bdnf mRNA; GFP reporter for neurite morphology",Measurement of Bdnf eIV-IX mRNA induction by qRT-PCR in cultured neurons; imaging of GFP-labeled neurons for morphological analysis,Molecular gene expression and cellular morphology functional assays,-,-,-,rat,Primary rat cortical neurons,cell culture,"
Deltamethrin: 1 nM to 100 μM (1 μM optimal); derivative 2a: 1 to 100 μM (10 μM optimal)",Deltamethrin caused up to ~10-fold higher Bdnf mRNA induction compared to derivative 2a; both increased neurite complexity and length similarly,-,Voltage-sensitive sodium channels leading to Ca2+ signaling,"Ion channels (VSSC), L-type calcium channels, ERK/MAPK signaling proteins",-,-,"Neuronal gene expression, neurite growth, neuronal plasticity","Real-time RT-PCR, fluorescence microscopy for GFP, neurite tracing",brain ,-,-,10.1016/j.bmc.2012.02.048,-,-,-
19,Lit_review,Deltamethrin,Pyrethroid,"ROS generation and cytotoxicity in human neuronal SH-SY5Y cells, and modulation by alpha-2-macroglobulin (α2M)","Assessment of pesticide (including deltamethrin)-induced reactive oxygen species (ROS) generation and cytotoxicity in human neuronal SH-SY5Y cells, and modulation by alpha-2-macroglobulin (α2M)",-,-,-,-,-,-,-,Deltamethrin exposure → increased ROS production → oxidative stress → neuronal cell injury and decreased viability → possible neurotoxicity,"Increased ROS levels, increased malondialdehyde (MDA) as lipid peroxidation marker, reduced antioxidant enzyme activities (SOD, GPx), decreased cell viability",Active,-,-,-,-,-,-,-,-,-,-,-, 5 μM,-,-,"MTT assay for cell viability; DCFH-DA fluorescence assay for ROS; TBARS assay for MDA; enzymatic assays for antioxidant enzymes (SOD, GPx)","Functional assays measuring cell viability, oxidative stress markers and antioxidant enzyme activity in human neuronal SH-SY5Y cell line",Cell-based cytotoxicity and oxidative stress functional assays,-,-,-,human ,SH-SY5Y ,cell line ,5 μM x 3 h (ROS) and x 6 h (viability),"Significant induction of ROS, increased MDA levels, reduced cell viability, and decreased activities of antioxidant enzymes; protection by α2M observed",-,-,-,-,-,"ROS generation, oxidative stress, antioxidant defense enzymes activity, cell viability","Colorimetric MTT assay, fluorometric DCFH-DA assay, absorbance-based TBARS assay, enzyme activity assays",brain ,-,-,10.15419/bmrat.v10i2.792,-,-,-
20,Lit_review,Deltamethrin,Pyrethroid,"Effects on motility, viability, and morphology of rat sperm","In vitro assessment of deltamethrin’s effects on rat sperm parameters (motility, viability, morphology), oxidative stress markers and antioxidant enzymes. Deltamethrin tested at multiple concentrations for 3-hour exposure on rat spermatozoa",-,-,-,-,-,-,-,"Deltamethrin exposure → induction of oxidative stress (lipid peroxidation) in sperm cells → altered antioxidant enzyme activities (SOD, CAT) → decreased sperm motility, viability and increased abnormalities",Significant decreases in sperm motility and viability; increase in abnormal sperm morphology; increased malondialdehyde (MDA) levels indicating lipid peroxidation; increased SOD and catalase enzyme activities,Active,-,-,-,-,-,-,-,-,-,-,-,200 μM,-,-,"Sperm motility, viability and morphology assessment; biochemical assays for lipid peroxidation and antioxidant enzymes (SOD, CAT)",,Evaluation of motility and viability by microscopic and staining methods; lipid peroxidation measured by malondialdehyde (MDA) quantification; antioxidant enzyme activities measured spectrophotometrically,-,-,-,rat,spermatozoa,"
Sperm suspensions","0, 10, 50, 100, 200 μM x 3h",Dose-dependent decline in sperm motility and viability; increased abnormal sperm morphology; elevated MDA levels; increased SOD and catalase activities,-,-,-,-,-,"Reproductive function via sperm motility, viability, morphology; oxidative stress response","Microscopy, staining, spectrophotometry (MDA assay, enzyme activity assays)",sperm,-,-,10.1111/j.1439-0272.2009.00986.x,-,-,-
21,Lit_review,Deltamethrin,Pyrethroid,"Oxidative stress induction, antioxidant defense modulation, and cytotoxicity in human endothelial cells","Assessment of oxidative stress induction, antioxidant defense modulation, and cytotoxicity in human endothelial cells (HUVEC) exposed to deltamethrin and other pesticides individually and in mixture",-,-,-,-,-,-,-,"Deltamethrin exposure leads to increased reactive oxygen species (ROS), decreased total antioxidant capacity (TAS), increased total oxidant status (TOS), depletion of glutathione (GSH), resulting in oxidative stress and cytotoxicity in endothelial cells","
Reduced cell viability (dose-dependent), increased ROS production, decreased antioxidant defense (TAS, GSH), increased oxidative damage markers (TOS)",Active,-,-,-,8.567 μM,-,-,-,-,-,-,-,200 μM ,-,-,"MTT cell viability assay; spectrophotometric measurement of oxidative stress markers (LDH, TAS, TOS); glutathione assay","Viability assessed by MTT; oxidative stress markers including lactate dehydrogenase activity (LDH), total antioxidant status (TAS), total oxidant status (TOS), and glutathione (GSH) evaluated in HUVEC cells",Cell viability and antioxidant capacity,-,-,-,human ,HUVEC,cell line ,"2.5, 5, 10, and 20 μM for viability; 25, 50, 100, 200 μM for oxidative stress markers",Dose-dependent decrease in viability; decrease in TAS and GSH; increase in TOS and LDH; significant oxidative stress induced by deltamethrin,-,-,-,-,-,"Cellular oxidative stress, antioxidant defense, cytotoxicity","MTT assay (colorimetric), spectrophotometry for enzymatic and oxidative stress assays",endothelium,-,-,10.26650/IstanbulJPharm.2021.881724,-,-,-
22,Lit_review,Deltamethrin,Pyrethroid,Behavioral toxicity assessment and gene expression analysis of voltage-gated calcium channel α1 subunits in Caenorhabditis elegans,"
Behavioral toxicity assessment and gene expression analysis of voltage-gated calcium channel (VGCC) α1 subunits (egl-19, unc-2, cca-1) in Caenorhabditis elegans exposed to deltamethrin",-,-,-,-,"egl-19, unc-2, cca-1",-,α1 subunits of voltage-gated calcium channels,"Deltamethrin exposure → altered expression of α1 subunits of VGCC → impaired locomotion, egg-laying, and foraging behavior in C. elegans","
Concentration-dependent decrease in locomotion (thrashing and body bend frequency), egg laying, and foraging; differential VGCC gene expression changes",Active,-,-,-,55.8 mg/L,-,-,-,-,-,-,-,400 mg/L,-,-,"Behavioral assays (thrashing, body bends, egg-laying, foraging) and RT-PCR gene expression assay","
Quantification of locomotion behavior, egg laying, foraging capability, and measurement of mRNA levels of VGCC α1 subunits via qRT-PCR in nematodes",Behavioral phenotyping and molecular gene expression analysis,-,-,-,C. elegans,-,whole body ,Tested range for toxicity 5–400 mg/L; sub-lethal doses 0.05–50 mg/L for gene expression and behavioral assays,Significant dose-dependent lethality; reduced thrashing and body bend frequency; decreased egg laying and foraging; differential up- and down-regulation of VGCC α1 subunit genes,-,-,-,-,-,"Neuromuscular function, egg-laying behavior, foraging behavior","
Behavioral assays (microscopy observation and counting); quantitative reverse transcription PCR (qRT-PCR)",whole nematode,-,-,10.1016/j.pestbp.2017.03.005,-,-,-
23,Lit_review,Deltamethrin,Pyrethroid,Developmental toxicity assessment in Caenorhabditis elegans,Developmental toxicity assessment of high-dose deltamethrin in Caenorhabditis elegans via ER unfolded protein response (UPRER) pathway analysis,-,-,-,-,"
ire-1, xbp-1, hsp-4, crt-1, T14G8.3, pek-1, atf-6",-,Genes involved in unfolded protein response endoplasmic reticulum (UPRER) pathway,"
High-dose deltamethrin exposure → developmental delay and toxicity → reduced activation of UPRER → downregulation of UPRER-related genes via IRE-1/XBP-1 pathway","Developmental retardation, reduced nematode size, prolonged egg-laying onset, reduced lifespan, decreased UPRER activation, altered gene expression of ER stress markers",Active,-,-,-,-,-,-,-,-,-,-,-,80 mg/L,-,-,"Developmental growth assays, lifespan and behavior assays, UPRER fluorescence reporter assay (hsp-4p::GFP), quantitative RT-PCR for ER stress genes","Measurement of body size, developmental stage distribution, lifespan, locomotion behaviors, fluorescent imaging of ER stress reporter, and expression of unfolded protein response genes",In vivo whole organism developmental and molecular toxicity assays,-,-,-,C. elegans,-,whole body ,"0, 5, 10, 20, 40, 80 mg/L; 40 mg/L for molecular assays","Developmental delay, growth retardation, reduced egg laying, decreased lifespan and locomotion, reduced UPRER activation, decreased transcript levels of ire-1 and other UPRER genes",-,Endoplasmic reticulum stress pathway proteins,Proteins/genes in UPRER pathway,IRE-1-mediated signaling components,UPRER gene regulatory network,"ER stress response, development, lifespan regulation","Fluorescent protein reporter assay, microscopy, quantitative RT-PCR",whole nematode,-,-,10.3390/molecules28176303,-,-,-
24,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,IC25,-,-,-,-,-,-,-,-,-,IC25 (nM)=5840,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,IC25 (nM)=5840,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
25,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,RIC20,-,-,-,-,-,-,-,-,-,RIC20 (nM)=13.2,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,RIC20 (nM)=13.2,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
26,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
27,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
28,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
29,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
30,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
31,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
32,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
33,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
34,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
35,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
36,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
37,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
38,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
39,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
40,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
41,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
42,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
43,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
44,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
45,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
46,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
47,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
48,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
49,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
50,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
51,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
52,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
53,ICE,Deltamethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
54,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR antagonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
55,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
56,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR antagonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
57,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
58,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR antagonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
59,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
60,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR antagonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
61,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR antagonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
62,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR antagonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
63,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
64,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
65,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR antagonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
66,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR antagonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
67,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
68,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR antagonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
69,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
70,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
71,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
72,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
73,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR antagonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
74,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR antagonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
75,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
76,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR antagonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Andersen et al. 2002; 11884232; 10.1006/taap.2001.9347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
77,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
78,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR antagonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
79,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
80,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR antagonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
81,ICE,Deltamethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8020381,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8020381
82,PARC,Cypermethrin,Pyrethroid,hNNF assay (hiPSC-derived neural network formation),"Effects of cypermethrin on neural network activity and formation (MEA): assessment of spike-, burst-, and network parameters; BMC calculation for most sensitive endpoint (MSE)",hNNF assay,"Chronic exposure of hiPSC-derived neurons and human astrocytes in defined co-culture to cypermethrin (0.027–20µM); weekly measurements; endpoints—network activity, cytotoxicity (LDH assay)",Assessment of developmental neurotoxicity by quantifying compound effects on spontaneous electrical activity and function of developing human neural networks,-,-,-,-,“Voltage-gated sodium channel modulation → impaired neural network function → behavioral impairment”; based on pharmacological MoA for pyrethroids,"Reduced neural network parameters (most sensitive: network burst duration, mean firing rate, etc.) reflecting voltage-gated sodium channel disruption",Positive—altered at least 1 network parameter (no cytotoxicity at hit concentration); “hit” if BMC50 for neural metric not overlapping with cytotoxicity,-,-,-,-,-,Benchmark response (BMR50): 50% change from baseline; BMC50 calculated as point of departure,-,-,"50% (BMR50 for reduction, BMR50ind for induction)","BMC50 for cypermethrin (hNNF, MSE): 11.72 µM (network burst frequency, Table 2)",-,20µM (no cytotoxicity observed),"Area under curve (AUC) normalized to solvent control, MEA activity metrics","IUF-Leibniz Research Institute for Environmental Medicine, Germany; DNTOX GmbH; NeuCyte Inc., USA",hNNF assay,"Weekly exposure of hiPSC-derived neuron:astrocyte networks to cypermethrin (0.027–20 µM), 35 days; MEA-based functional and cytotoxicity endpoints; BMC modeling","Functional neurotoxicity profiling (MEA, electrophysiology, network function)",“Positive” if BMC50 for network parameter observed without cytotoxicity,20,mM,human,"hiPSC-derived glutamatergic neurons, GABAergic neurons, and primary human astroglia","co-culture: 52% glutamatergic, 22% GABAergic, 26% astrocyte;","0.027, 0.082, 0.247, 0.74, 2.22, 6.67, 20µM","Concentration-dependent reduction in network parameters (most sensitive: burst frequency, BMC50 = 11.72µM)",No overt cytotoxicity at relevant concentrations (LDH assay negative for cell death),"Voltage-gated sodium channels, neuronal firing networks","Ion channel modulator, neurodevelopmental toxicant",Sodium channel subtype interference ,-,"Neural network formation, synaptic activity, network bursting/firing",Multi-electrode array (MEA) for extracellular electrical activity,In vitro model for developing human brain (mixed neuron/astrocyte culture),-,"2–3 independent experiments, 3 technical replicates each ",doi:10.14573/altex.2206031  ,-,-,-
83,BioStudies,Cypermethrin,Pyrethroid,Effect on neural network development in rat cortical cultures as measured by 17 electrophysiological network parameters,Screening for developmental neurotoxicity (DNT) via perturbation of neural network function using MEA; viability measured by Alamar Blue/LDH,Effect on neural network development in rat cortical cultures,Screening for developmental neurotoxicity (DNT) via perturbation of neural network function using MEA; viability measured by Alamar Blue/LDH,-,-,-,-,-,Disruption of neural network development (general DNT context),"
Network development disruption; reduced neural activity",Active,-,-,-,"26,25 μM",-,-,-,-,-,-,-,30μM,Network activity values normalized to plate controls,"Frank et al., US EPA Integrated Systems Toxicology Division",Microelectrode array-based neural network formation assay,"Rat cortical cells cultured and exposed to cypermethrin, monitored for spontaneous activity, synchrony, and cell viability as network formed (12DIV)",Functional neurotoxicity screening,-,30,mM,rat,Primary cortical neurons (plus glia),primary mixed cells,"0.03μM, 0.1μM, 0.3μM, 1μM, 3μM, 10μM, 30μM",Cypermethrin disrupts neural network activity in a concentration-dependent manner; specific network parameters altered at sub-cytotoxic concentrations,Cytotoxicity (Alamar Blue/LDH) measured at DIV12 for highest concentrations; network effects observed below cytotoxic concentrations,-,-,-,-,"Neural network development, synaptic function, neural coordination","Electrophysiology, metabolic activity, enzymatic lysis",brain,-,-,https://doi.org/10.1093/toxsci/kfx169,DNT,-,-
84,BioStudies,Cypermethrin,Pyrethroid, Neural network development; identification of toxicological tipping points where network recovery fails.,"9 primary network activity parameters: mean firing rate (MFR), number of active electrodes (#AE), burst rate (BR), number of actively bursting electrodes (#ABE), percent of spikes in bursts (%SiB), number of network spikes (#NS), percent of spikes in network spikes (%SiNS), Pearson correlation (r), mutual information (MI)", Neural network development; identification of toxicological tipping points where network recovery fails.,"Parameters reflect spontaneous spiking, bursting, synchrony, and connectivity in developing networks recorded using MEAs.",-,-,-,-,-,network function disruption as an early key event for developmental neurotoxicity (DNT),Disruption of spontaneous neural network formation and function during early in vitro development,Active,-,-,-,-,-,-,-,-,-,-,-,30μM ,"Z-scored, plate-normalized fold-change vs. controls for each network paramete",US EPA Integrated Systems Toxicology Division,Microelectrode Array Neural Network Development Assay (mwMEA),Medium-throughput assay quantifying disruption of network development in primary rat cortical cultures by monitoring electrical activity over 12 days in vitro,"Functional, physiological neurotoxicity screening",-,-,-,rat,Primary mixed cortical neuron culture,primary culture,Tipping point (critical concentration) at 0.283 μM (DIV9 to DIV12); 95% CI: 0.188 – 0.379 μM,Concentration-dependent irrecoverable disruption of neural network activity and formation observed,Tipping point at 0.283 μM is below the cytotoxicity threshold (≥50% loss of cell viability) indicating functional disruption precedes cytotoxicity,"Nervous system related targets (likely ion channel modulators, consistent with pyrethroid MoA)",Voltage-gated sodium channel modulator ,-,-,Neural network formation; developmental neurotoxicity screening,Microelectrode array (MEA) extracellular electrophysiology,brain,-,-,https://doi.org/10.1016/j.taap.2018.01.017,DNT,-,-
85,Lit_review,Cypermethrin,Pyrethroid,WST-test and total ATP measure,"The total ATP assay measures cell viability by quantifying the amount of adenosine triphosphate (ATP), a marker of metabolically active living cells. The WST test (Water-soluble Tetrazolium salt assay) is a colorimetric assay to assess cell viability and proliferation. It uses tetrazolium salts (e.g., WST-1 or WST-8) that are reduced by mitochondrial dehydrogenases in viable cells to produce a water-soluble formazan dye. The amount of dye produced correlates with the number of metabolically active cells and is quantified by measuring absorbance using a spectrophotometer. ",-,-,-,-,-,-,-,-,cytotoxicity (low total ATP and mitocondrial metabolic activity),Active,-,-,-,-,-,-,-,-,-,-,-,100μM,-,-,Total ATP and WST-test,"The total ATP assay measures cell viability by quantifying the amount of adenosine triphosphate (ATP), a marker of metabolically active living cells. It utilizes the bioluminescent reaction catalyzed by the enzyme luciferase in the presence of ATP and luciferin, producing light proportional to ATP concentration. As ATP is rapidly depleted in dead or dying cells, the luminescent signal directly correlates with the number of viable cells. The WST test (Water-soluble Tetrazolium salt assay) is a colorimetric assay to assess cell viability and proliferation. It uses tetrazolium salts (e.g., WST-1 or WST-8) that are reduced by mitochondrial dehydrogenases in viable cells to produce a water-soluble formazan dye. The amount of dye produced correlates with the number of metabolically active cells and is quantified by measuring absorbance using a spectrophotometer.",viability ,-,-,-,human ,SH-SY5Y,cell line ,0.1-100μM,"There was induction of enzyme activities with WST-1 test with all pyrethroid compounds studied at low concentrations. With the ATP assay, exposure to 0.1-100μM of natural pyrethrin, as well as of permethrin and cypermethrin showed dose-dependent cytotoxicity. The most toxic pyrethroid was cypermethrin followed by permethrin and natural pyrethrin.",-,-,-,-,cytotoxicity,cell death,"Luminescence (total ATP), photometry (WST-test), microscopy (morphological changes)",brain,-,-,10.1016/j.etap.2003.11.005,-,-,-
86,Lit_review,Cypermethrin,Pyrethroid,WST-test and total ATP measure,"The proliferation of the breast cancer cell line, MCF7, was studied after a 7-day exposure to various concentrations of pyrethrin, permethrin and cypermethrin. The effects of oestradiol and the combined effects of oestradiol (0.10 nM) and pyrethroids (0.1-100 microM) on MCF7 cell proliferation were also evaluated. The total ATP assay measures cell viability by quantifying the amount of adenosine triphosphate (ATP), a marker of metabolically active living cells. The WST test (Water-soluble Tetrazolium salt assay) is a colorimetric assay to assess cell viability and proliferation. It uses tetrazolium salts (e.g., WST-1 or WST-8) that are reduced by mitochondrial dehydrogenases in viable cells to produce a water-soluble formazan dye. The amount of dye produced correlates with the number of metabolically active cells and is quantified by measuring absorbance using a spectrophotometer. ",-,-,-,-,-,-,-,-,cytotoxicity (low total ATP and mitocondrial metabolic activity),Active,-,-,-,-,-,-,-,-,-,-,-,100μM,-,-,Total ATP and WST-test,"The total ATP assay measures cell viability by quantifying the amount of adenosine triphosphate (ATP), a marker of metabolically active living cells. It utilizes the bioluminescent reaction catalyzed by the enzyme luciferase in the presence of ATP and luciferin, producing light proportional to ATP concentration. As ATP is rapidly depleted in dead or dying cells, the luminescent signal directly correlates with the number of viable cells. The WST test (Water-soluble Tetrazolium salt assay) is a colorimetric assay to assess cell viability and proliferation. It uses tetrazolium salts (e.g., WST-1 or WST-8) that are reduced by mitochondrial dehydrogenases in viable cells to produce a water-soluble formazan dye. The amount of dye produced correlates with the number of metabolically active cells and is quantified by measuring absorbance using a spectrophotometer.",viability ,-,-,-,human ,MCF7,cell line ,0.1-100μM,"n the ATP test, low concentrations (0.1-1 microM) of pyrethroids in co-exposure with oestradiol caused a clear statistically significant increase in the proliferation of MCF7 cells. This was evident when compared to the proliferative effect caused by 0.1 nM oestradiol alone. High concentrations were cytotoxic, and the greatest cell toxicity was that of cypermethrin, which has a cyano group in its molecular structure.",-,mitochondrial metabolic enzymes,-,-,cytotoxicity,cell proliferation and toxicity,"Luminescence (total ATP), photometry (WST-test)",breast ,-,-,10.1177/026119290403200410,-,-,-
87,Lit_review,Cypermethrin,Pyrethroid,"Effects on neuronal network formation, transcriptomic and metabolomic changes related to developmental neurotoxicity","Functional neuronal networks grown in vitro, assessed for network activity, gene expression (RNA-seq), and metabolomic changes after chemical exposure",Rat primary cortical neural networks cultured on microelectrode arrays (MEAs),"Effects of cypermethrin on network activity via MEA recordings over 12 days, coupled with transcriptomic and metabolomic profiling at the end of exposure",-,-,"SOX2, PRODH, ATXN1, CREB1, etc.",-," SOX2 (transcription factor), PRODH (proline dehydrogenase), ATXN1 (ataxin 1), CREB1 (cAMP response element binding protein 1), ETC.",-,-,Active,-,-,-,-,-,-,-,-,-,-,-,10 µM,-,-,Neural Network Formation Assay (NFA),Multiparametric assay measuring development of neuronal network function via electrophysiology combined with transcriptomic and metabolomic profiling following chemical exposure,developmental,-,30,mM,rat,Primary neocortical cultures,primary culture,0.03-10 µM,"Concentration-dependent decreases in multiple parameters of network activity (e.g., mean firing rate, bursting activity), changes in gene expression and metabolomic profiles indicating disruption of neuronal development",-,-,-,-,neural network function and development,"Neuronal network formation,","Electrophysiology  (MEA), RNA sequencing (RNA-seq), gas chromatography-mass spectrometry (GC-MS)",brain,-,-,10.1093/toxsci/kfab151,-,-,-
88,Lit_review,Cypermethrin,Pyrethroid,WST-test and total ATP measure,"The total ATP assay measures cell viability by quantifying the amount of adenosine triphosphate (ATP), a marker of metabolically active living cells. The WST test (Water-soluble Tetrazolium salt assay) is a colorimetric assay to assess cell viability and proliferation. It uses tetrazolium salts (e.g., WST-1 or WST-8) that are reduced by mitochondrial dehydrogenases in viable cells to produce a water-soluble formazan dye. The amount of dye produced correlates with the number of metabolically active cells and is quantified by measuring absorbance using a spectrophotometer. ",-,-,-,-,-,-,-,-,cytotoxicity (low total ATP and mitocondrial metabolic activity),Active,-,-,-,-,-,-,-,-,-,-,-,100μM,-,-,Total ATP and WST-test,"The total ATP assay measures cell viability by quantifying the amount of adenosine triphosphate (ATP), a marker of metabolically active living cells. It utilizes the bioluminescent reaction catalyzed by the enzyme luciferase in the presence of ATP and luciferin, producing light proportional to ATP concentration. As ATP is rapidly depleted in dead or dying cells, the luminescent signal directly correlates with the number of viable cells. The WST test (Water-soluble Tetrazolium salt assay) is a colorimetric assay to assess cell viability and proliferation. It uses tetrazolium salts (e.g., WST-1 or WST-8) that are reduced by mitochondrial dehydrogenases in viable cells to produce a water-soluble formazan dye. The amount of dye produced correlates with the number of metabolically active cells and is quantified by measuring absorbance using a spectrophotometer.",viability ,-,-,-,human ,SH-SY5Y,cell line ,0.1-100μM,"There was induction of enzyme activities with WST-1 test with all pyrethroid compounds studied at low concentrations. With the ATP assay, exposure to 0.1-100μM of natural pyrethrin, as well as of permethrin and cypermethrin showed dose-dependent cytotoxicity. The most toxic pyrethroid was cypermethrin followed by permethrin and natural pyrethrin.",-,mitochondrial metabolic enzymes,-,-,cytotoxicity,cell death,"Luminescence (total ATP), photometry (WST-test), microscopy (morphological changes)",brain,-,-,10.1016/j.etap.2003.11.005,-,-,-
89,Lit_review,Cypermethrin,Pyrethroid,"DNA damage (strand breaks, as measured by comet assay).","Alkaline comet assay measuring DNA strand breaks (genotoxicity) in human peripheral lymphocytes exposed in vitro to cypermethrin at multiple concentrations, scored for DNA damage categories and total comet score (TCS)",Alkaline comet assay,Quantification of DNA migration (comet tail) in lymphocytes as an indicator of DNA strand breaks post-exposure to cypermethrin.,-,-,-,-,-,-,genotoxicty (DNA strand breaks),Active,-,-,-,-,-,-,-,-,-,-,-,10 µM,"Total comet score (TCS),",-,In vitro alkaline comet assay,"Primary human lymphocytes exposed to cypermethrin at 1, 5, and 10 µM; DNA migration scored by comet assay after 1-hour exposure",genotoxicity,-,-,-,human ,Peripheral blood lymphocytes,primary culture,"1, 5, and 10 µM",DNA damage as mean total comet score with SD; significant increase at 10 µM only,No,-,-,-,genotoxicity,DNA repair/strand break induction,Fluorescence,peripheral lymphocytes,-,-,10.1002/tox.20569,-,-,-
90,Lit_review,Cypermethrin,Pyrethroid,VGCC-mediated Ca2+2+ influx.,"Inhibition of voltage-gated calcium channel (VGCC)-mediated Ca2+2+ influx in PC12 cells after subchronic (24 h) and repeated (24 h + acute) exposure to cypermethrin, measured as reduction in K++-evoked intracellular Ca2+2+ increase using Fura-2 fluorescence imaging.",-,-,-,-,-,-,-,Calcium influx inhibition in neurons,Inhibition of neuronal calcium signaling via VGCCs,Active,-,-,-,"Subchronic (24 h): 0.93 µM
Repeated (24 h + acute): 0.097 µM
",-,-,-,-,IC20 (20% inhibition):Subchronic: 0.25 µM; Repeated: 0.006 µM; Acute: 0.006 µM,-,-,11 µM,Net Ca2+2+ influx normalized to % control.,-,Fura-2-based single-cell calcium imaging VGCC inhibition assay in PC12 cells.,,Assay measures the reduction in high-K++-evoked Ca2+2+ influx in PC12 cells after exposure,-,-,-,rat,PC12,cell line ,"0.001, 0.01, 0.1, 1, 10 µM","cypermethrin inhibited VGCC-mediated Ca2+ influx at subchronic and repeated exposure, with significant effects starting at 1 µM for subchronic and 0.006 µM for repeated",-,Ion channel,Voltage-gated calcium channel,"L-, N-, P/Q-type VGCCs",-,Neuronal calcium influx; synaptic signaling,Fluorescence,adrenal medulla,-,-,10.1093/toxsci/kfv154,-,-,-
91,Lit_review,Cypermethrin,Pyrethroid,Genotoxic effects measured by cytokinesis-block micronucleus cytome (CBMN-cyt) assay,"Cytogenetic markers of DNA damage, chromosomal instability, and cell division alteration. Micronuclei indicate chromosomal breaks or loss, nuclear buds indicate gene amplification or excision, irregular nuclei indicate nuclear abnormality.","Micronucleus formation (BNMn), nuclear buds (BNBud), binucleated cells with irregular nuclei (BNIrr), binucleated cells with micronucleus + bud (BNMn + BNBud), nucleoplasmic bridges (BNBridge).",-,-,-,-,-,-,-,"Chromosomal breakage, micronucleus formation, and mitotic dysfunction as key events ",Active,-,-,-,-,-,-,-,-,-,-,-,175 μg/mL (≈ 420 μM),frequencies,-,CBMN-cyt assay,"Micronucleus and nuclear anomaly frequency quantification after 72-hour in vitro exposure of bovine lymphocytes to cypermethrin at five concentrations, using established CBMN protocols",genotoxicity,-,-,-,bovine,Peripheral blood lymphocytes,primary culture,"10.9, 21.8, 43.7, 87.5, 175.0 μg/mL x 72h",cypermethrin induced significant increases in BNMn and BNIrr at 87.5 and 175 μg/mL,-,-,-,-,genotoxicity,"Chromosome segregation, DNA repair, cell cycle progression",Microscopy,peripheral blood,-,-,10.1016/j.chemosphere.2019.125341,-,-,-
92,Lit_review,Cypermethrin,Pyrethroid,"MTT assay, Western Blot (WB)",Viability assay and quantification of proteins implicated in cell death regulation,-,-,-,-,-,-,-,-,-,Active (mixture of substances),-,-,-,-,-,-,-,-,-,-,-,3 µM,-,-,MTT and WB," MTT assays measure cellular metabolic activity to assess cell viability and proliferation by detecting a color change, while Western Blotting detects and quantifies specific proteins within a complex biological sample using gel electrophoresis and antibodies. ",viability ,-,100,mM,human ,SH-SY5Y,cell line ,"CM (1.75, 2.5, 3 µM) or CPF+CM (17.5+1.75, 25+2.5, 30+3.0 µM) X 24 hr","It was found that chlorpyrifos (CPF) and its mixture with cypermethrin (CPF+CM) induced cell death of SH-SY5Y cells in a dose- and time-dependent manner, as shown by MTT assays. Pesticideinduced SH-SY5Y cell death was characterized by concentration-dependent down-regulation of Bcl-2 and Bcl-xL as well as an increase in the caspase 3 activation. Pan-caspase inhibitor Q-VD-OPh produced a slight but significant reversal effect of pesticide-induced toxicity indicating that the major caspase pathways are not integral to CPF- and CPF+CM-induced cell death. Furthermore, signal transduction inhibitors PD98059, SL-327, SB202190, SP600125 and mecamylamine failed to attenuate pesticides effect",-,-,-,-,cytotoxicity,cell death,Colorimetry,brain,-,-,10.1111/bcpt.12285,-,-,-
93,Lit_review,Cypermethrin,Pyrethroid, Colony Forming Ability (CFA) assay,"in vitro technique to assess the long-term survival, proliferation, and cytotoxic effects of chemical treatments on cells. The assay measures the ability of a single viable cell to undergo unlimited division and form a colony consisting of at least 50 cells. This ability reflects the reproductive viability and proliferative capacity of the cells following exposure to a test compound.",-,-,-,-,-,-,-,-,cell cycle arrest,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,colony forming ability (CFA) assay + cell cycle analysis by flow cytometry + microscopic evaluation of the mitotic index.,"CFA assay is a widely used in vitro technique to assess the long-term survival, proliferation, and cytotoxic effects of chemical treatments on cells. The assay measures the ability of a single viable cell to undergo unlimited division and form a colony consisting of at least 50 cells. This ability reflects the reproductive viability and proliferative capacity of the cells following exposure to a test compound.",viability ,-,-,-,hamster,V79,cell line ,3.1–100 mg/ml,"The colony forming ability (CFA) resulted in distinct differences of the cytotoxic effect of the tested pyrethroids, whereby permethrin was found to be most toxic. With the exception of fenvalerate all tested pyrethroids gave rise to inhibition of cell cycle progression as shown by G2/M-arrest of synchronized V79 cells by flow cytometry as well as by the increase of the mitotic index as evaluated by light microscopy. ",-,-,-,-,cytotoxicity,cell cycle,Fllow-cytometry and microscopy,lung,-,-,https://doi.org/10.1016/S0378-4274(99)00034-X,-,-,-
94,Lit_review,Cypermethrin,Pyrethroid,MTT and LDH release assays,MTT assay to assess cell viability/cytotoxicity and LDH release assay for membrane integrity. Confocal and light microscopy used for morphological assessment.,-,-,-,-,-,-,-,-,cytotoxicity ,Active,-,-,-, 23.7 ng/mL,-,-,-,-,-,-,-,200 ng/mL ,-,-,"MTT assay, LDH release, EROD activity (CYP1A), microscopy",MTT: Mitochondrial function and cell viability. LDH: Membrane damage/cell lysis during apoptosis/necrosis. EROD: Measurement of CYP1A induction indicating biotransformation/phase I metabolic capacity. Microscopy: Morphological characterization of cellular/subcellular alterations,"viability, cytotoxicity, and enzyme induction",-,10,mg/mL,trout,RTG-2,cell line ," 6.25, 12.5, 25, 50, 100, 200 ng/mL for toxicity assays; IC50 for microscopy/EROD (105.3 ng/mL)","IC50 (MTT, cypermethrin): 23.7 ng/mL (most cytotoxic of all tested pyrethroids). LDH release: 88.02 ± 11.98% (but not dose-dependent). EROD activity (CYP1A) at IC50: 33.42 ± 0.14 pmol/min/mg; maximal fold induction vs control: 4.28 ± 0.02. Morphological effects: Fragmented cytoskeleton, condensed nuclei, pyknotic nuclei, shrinkage, micronucleus formation, loss of normal cell structure at IC50.",-,-,-,-,-,-,Colorimetric (MTT/LDH); Fluorometric (EROD); Microscopy,Gonadal/mixed testis-ovary cells,-,-,https://doi.org/10.1080/15569543.2017.1366922,-,-,-
95,Lit_review,Cypermethrin,Pyrethroid,Genotixicity and chromosomal damage with the cytokinesis-block method to assess micronulie formation after exposure to pyrethroids,"The cytokinesis-block method with 6 μg/ml cytochalasin B (Cyt-B) is a widely used technique in the cytokinesis-block micronucleus (CBMN) assay to assess chromosomal damage and genotoxicity. Cytochalasin B is a drug that inhibits actin polymerization, specifically blocking the formation of the contractile ring required for cytokinesis (the final step of cell division where the cytoplasm divides). By adding Cyt-B to cultured cells at a concentration of about 6 μg/ml, cytokinesis is prevented while nuclear division proceeds normally, resulting in the accumulation of binucleated cells, i.e., cells with two nuclei.",-,,-,-,-,-,-,-,micronucleus formation (MN) and cytotoxicity,Active,-,-,-,-,-,-,-,-,-,-,-,200  μg/mL,-,-,cytokinesis-block micronucleus (CBMN) assay,"It is a well-established cytogenetic assay that detects chromosomal damage by scoring micronuclei in binucleated cells, providing sensitive measurement of genetic damage caused by chemical agents such as insecticides in human lymphocyte cultures",viability ,-,-,-,human ,whole blood and lymfocytes,peripheral blood lymphocytes ,10-200  μg/mL,"At the concentration ranges tested, all the five pyrethroids induced clear dose dependent cytotoxic effects, fenpropathrin being the most toxic. Nuclear division index (NDI) and the newly introduced index of cytotoxicity, the cytokinesis block proliferation index (CBPI), reflected the dose dependency more accurately than the percentage of binucleated cells did.",-,-,-,-,cytotoxicity,cell cycle/proliferation,Fluorescence,blood,-,-, 10.1016/0165-1218(95)90007-1,-,-,-
96,Lit_review,Cypermethrin,Pyrethroid,Cytotoxicity assessed by cell viability; protective efficacy against pyrethroid cytotoxicity,MTT cytotoxicity assay measuring cell viability after exposure to insecticides including permethrin; enzymatic assays for P450 detoxification activity on Sf9 insect cells engineered to express mosquito P450 enzymes CYP6P7 or CYP6AA3. They were used to test detoxification capacity.,-,-,-,-,"CYP6P7, CYP6AA3",-,Cytochrome P450 monooxygenases CYP6P7 and CYP6AA3,Detoxification of permethrin by cytochrome P450 enzymes reduces cytotoxicity; inhibition of P450 increases cytotoxicity,"Cytoprotection from cytotoxicity, enzymatic metabolism of permethrin",Active,-,-,-,-,-,-,-,-,-,-,-,500 µM,Cell viability percentage,-,"MTT cytotoxicity assay, in vitro enzymatic reconstitution assay",Measurement of cytotoxicity and detoxification enzyme activity against permethrin in Sf9 insect cells,"viability, detoxification capability assessment",-,-,-,Spodoptera frugiperda,Sf9 ,cell line ,0.1-500 µM x 72h," The results revealed that CYP6P7- or CYP6AA3-expressing cells showed significantly higher cytoprotective capability than parental Sf9 cells against cytotoxicity of pyrethroids including permethrin, cypermethrin and deltamethrin. Such cytoprotective effect was not observed for chlorpyrifos. Moreover, expression of CYP6AA3, but not CYP6P7, could protect cells against λ-cyhalothrin cytotoxicity. In MTT assays upon co-incubation with piperonyl butoxide (P450 inhibitor), cytoprotective ability of CYP6P7 and CYP6AA3 against deltamethrin was diminished, implying that pyrethroid detoxification was due to activities of P450 enzymes. ",-,Cytochrome P450 enzymes,Enzymes,Monooxygenases,cytotoxicity,"Xenobiotic metabolism, detoxification",Colorimetric MTT assay,insect cells,-,-,https://pubmed.ncbi.nlm.nih.gov/22041748/,-,-,-
97,Lit_review,Cypermethrin,Pyrethroid,"Inhibition of housefly-head acetylcholinesterase (AChE) activity, measured by reduction in enzymatic activity",Acetylcholinesterase inhibition bioassay,-,-,-,-,-,-,-,-,AChE activity inhibition,Active (mixture of substances),-,-,-,-,-,-,-,-,-,-,-,10 mg/L fixed as maximum cypermethrin concentration used in mixtures; not tested as single substance,-,-,Housefly-head AChE in vitro inhibition assay,Microplate-based assay measuring residual AChE activity after 10-min pesticide exposure using DTNB/ATCh read at 405 nm,"
Functional enzyme inhibition",,4–5,g/L,housefly,purified tissue from head,cell lisate,0.1 mg/L and 10 mg/L in binary combinations with OP/CB pesticides,"Synergistic increase in AChE inhibition potency of OP/CB partners, especially for chlorpyrifos (CPF), triazophos (TRZ), malathion (MLT)",-,Enzyme (hydrolase),Acetylcholinesterase inhibitor ,-,-,synaptic function/neurotransmission,Colorimetric enzyme assay,insect head extract,-,3 experiments × 3 replicates,10.1016/j.toxlet.2016.12.009,-,-,-
98,Lit_review,Cypermethrin,Pyrethroid,Vital physiological parameters and oxidative balance,"Egg laying, brood size, feeding and lifespan and oxidative stress parameters such as ROS, hydrogen peroxide levels, protein carbonyl, enzymatic antioxidants and glutathione levels",-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,15 mM,-,-,"Measurement of oxidative stress markers by colorimetric assays, egg laying assay, brood size, feeding assay, lifespan, protein stimation ",-,general state of physiological functions,-,-,-,C.elegans,-,full body homogenate,"1, 5, 15 mM x 4h","There was a significant and dose-dependent decrease in brood size (18–53%), egg laying (54–67%), feeding (29–58%) and marked decrease in lifespan (20%) at 15 mM of cypermethrin. Increase in levels of oxidative markers such as ROS (21–56%), intracellular hydrogen peroxide (17–62%), protein carbonyl (8–29%) and alteration in the activity of enzymatic antioxidants as well as depletion of glutathione (13–38%) were also observed.",-,-,-,-,-,several physiological processess and oxidative balance,Colorimetry oxidation analysis,whole body,-,-,10.1016/j.pestbp.2010.03.002,-,-,-
99,Lit_review,Cypermethrin,Pyrethroid,Vital physiological parameters,"Egg hatching rate, larval growth, and larval survival in a damselfly, Ischnura elegans, and on survival of a crustacean, Daphnia magna.",-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,0.15 mg/mL,-,-,"egg hatching rate, larval growth, and larval survival in Ischnura elegans, and on survival of Daphnia magna",-,development and survival,-,-,-,Ischnura elegans and Daphnia magna,-,-,"0.15, 0.015, 0.0015 mg/Lx pulse exposition","n, Daphnia magna. Insecticide exposure had significant negative effects on hatching rate in damselfly eggs. Exposed damselfly larvae also grew less and showed a higher mortality than control larvae. In Daphnia, the acute toxicity test (ISO 6341 in Water quality— determination of the inhibition of the mobility of Daphnia magna Straus (Cladocera, Crustacea)—acute toxicity test, Int Organ Stand Geneve, Geneva, 2012) showed an increased inhibition of mobility in the presence of insecticides. We observed a proportional response in relation to insecticide concentration, such that the highest exposure levels showed the largest reduction of vital performances. Our highest tested values correspond to those currently employed in agriculture.",-,-,-,-,-,development and survival,-,whole body,-,-,https://doi.org/10.1007/s10333-018-0678-3,-,-,-
100,Lit_review,Cypermethrin,Pyrethroid,Vital physiological parameters,"brood size, percentage of gravid nematodes, expression of reproductive-related genes and vitellogenin trafficking and endocytosis ",-,-,-,-,"vit-2, cpb-3, hus-1, spe-11, etc.",-,"genes: vitellogenin 2, cytoplasmic polyadenylation element binding protein 3, hus1 checkpoint clamp component B, spermatocyte protein spe-11 ",-,-,Active,-,-,-,-,-,-,-,-,-,-,-,100 μg/L,-,-,"Brood size measurement, determination of the percentage of gravid nematodes, reverse transcriptase real-time PCR analysis, vitellogenin distribution and endocytosis",-,"development, survival, and endocrine disruption",-,-,-,C.elegans,-,-,"0.1, 1, 10 and 100 μg/L","Results showed that all the pesticides disturbed to some extent one or more of the evaluated endpoints. Cypermethrin had the least impact on the evaluated endpoint. Cypermethrin affected the brood size at the highest concentration tested and mancozeb altered the distribution of vitellogenin only in approximately 10% of the population. However, both products overexpressed hus-1 and vit-2 genes, indicating that an induction of stress could interfere with the normal development of the nematode. ",-,Estrogens,-,-,-,endocrine processes,-,whole body,-,-,10.1016/j.tox.2022.153229,-,-,-
101,Lit_review,Cypermethrin,Pyrethroid,"Chromosome structural aberrations (CAs), sister chromatid exchanges (SCEs), cell cycle delay (proliferative rate index)","In vitro cytogenetic assays scoring well-spread metaphase chromosomes stained with Giemsa (CAs) and fluorescence plus Giemsa (SCEs), plus calculation of proliferative rate index",-,-,-,-,-,-,-,-,"Chromosome breaks, exchanges, gaps; sister chromatid exchange frequency changes; cell proliferation delay",Active,-,-,-,-,-,-,-,-,-,-,-,50 µg/ml,-,-,Cytogenetic analysis of chromosome aberrations and sister chromatid exchanges in cultured human lymphocytes,"in vitro cytogenetic assays scoring well-spread metaphase chromosomes stained with Giemsa (CAs) and fluorescence plus Giemsa (SCEs), plus calculation of proliferative rate index",viability,-,-,-,human ,Peripheral blood lymphocytes,primary culture,"2, 4, 10, 20, 40, 50 µg/ml ",No significant increase in chromosome aberrations or SCEs compared to controls. Both insecticides caused cell cycle delay evidenced by reduced proliferative rate index at >10 µg/ml. Increased micronuclei were not reported.,-,-,-,-,-, genome integrity and cell cycle,"Cytogenetic microscopic analysis (Giemsa staining for metaphase chromosomes, fluorescence microscopy for sister chromatid exchanges)",blood,-,-,10.1093/mutage/4.1.72,-,-,-
102,Lit_review,Cypermethrin,Pyrethroid,Apoptosis and Cell proliferation,"flow cytometry using an apoptosis detection kit and Cell proliferation (PI) was evaluated by 5-(and
6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) fluorescence decay using flow
cytometry. ",-,-,-,-,-,-,-,-,Cell proliferation or apoptosis,Inactive,-,-,-,-,-,-,-,-,-,-,-,4 µg/mL,-,,Cell proliferation (PI) assay,Cell proliferation (PI) was evaluated by 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) fluorescence decay using flow cytometry. ,proliferation,-,-,-,human ,Peripheral blood lymphocytes,primary culture,"0.5, 1.0, 2.0, 2.5 and 4 µg/ml","In vitro treatment of peripheral blood mononuclear cells with cypermethrin, at the doses tested, does not affect cell viability or proliferation",-,-,-,-,-,proliferation,flow cytometry,blood,-,-,10.3109/01480545.2015.1022897,-,-,-
103,Lit_review,Cypermethrin,Pyrethroid,"Cell death (apoptosis), ROS induction, etc.","Cell growth inhibition, induction of apoptosis, ROS production, activation of redox and detoxification genes, pluripotency and differentiation marker expression",-,-,-,-,"Cat, Sod1, Sod2, Gpx1, Gpx4, etc.",-,"Catalase, Superoxide dismutase [Cu-Zn], Superoxide dismutase [Mn], Glutathione peroxidase 1, Glutathione peroxidase 4, etc.",-,disruption of cell diferentiation,Active ,-,-,-,"LD50=  300 µM for R1, 600 µM for 3T3",-,-,-,-,-,-,-,"
1 mM",-,-,Cypermethrin exposure toxicity assay in mouse stem cells ,"72 h exposure to cypermethrin at LD50 dose; measured cell growth, apoptosis (Annexin V/PI), ROS production (H2DCFDA), gene expression (qPCR) ","Phenotypic toxicity, mechanistic gene expression profiling",-,100,mM,mice,R1 mESC + NIH/3T3,cell lines,"0.3 mM (R1), 0.6 mM (3T3); tested up to 1 mM","Cell death, loss of growth, increase in ROS, changes in gene expression ",-,"Cytochrome P450 family, antioxidant systems ",,-,-,"Oxidative stress response, apoptosis, stem cell pluripotency, early differentiation (germ layers) ","Flow cytometry, absorbance, qPCR (SYBR Green)",blastocyst/embryo,-,-,10.4081/ejh.2020.3084,-,-,-
104,Lit_review,Cypermethrin,Pyrethroid,Cytotoxicity and induction of CYP1A1/2 expression ,"Cytotoxicity (cell viability by Neutral Red and MTT tests); induction of CYP1A1/2 expression (ethoxyresorufin O-deethylase [EROD] activity, mRNA)",-,-,-,-,"
CYP1A1, CYP1A2",-,"Cytochrome P450 1A1, Cytochrome P450 1A2","Activation of xenobiotic metabolic pathway (CYP1A induction), phase I metabolism, potential for reactive metabolite formation",Induction of CYP1A1/2 activity and mRNA; mild increase in EROD enzymatic activity; no cytotoxicity at tested concentrations,Active  (for CYP1A1/2 induction); Inactive (for cytotoxicity at tested concentrations),-,-,-,-,-,-,-,-,-,-,-,100 μM for CYP induction; cytotoxicity curve up to 1000 μM,-,-,Neutral Red cytotoxicity assay; MTT cytotoxicity assay; EROD activity assay; Northern blot for mRNA,"Evaluation of viability (NR, MTT) after 48 hr exposure, and CYP1A1/2 induction (EROD activity, mRNA by Northern blot) post 3-day exposure",Cytotoxicity assay; xenobiotic metabolic enzyme induction assay,-,-,-,human + rat,"
Primary hepatocytes",primary culture,"1, 10, 100, 250, 1000 μM (viability); 1–100 μM (EROD and mRNA induction)",~2.5–3 fold induction of EROD activity at 100 μM CPR (compared to 16-fold for positive control 3-MC); no significant cytotoxicity in human cells,-,Cytochrome P450 (CYP) system,-,-,-,Xenobiotic metabolism; phase I oxidation of chemicals/toxins; gene expression regulation in liver,"Colorimetric/fluorometric (NR, MTT, EROD enzymatic activity); nucleic acid hybridization (Northern blot)",liver,-,-,https://doi.org/10.1016/S0887-2333(97)00061-1,-,-,-
105,Lit_review,Cypermethrin,Pyrethroid,immunotoxicity determined via gene expression changes using qRT-PCR,Direct immunotoxicity determined via gene expression changes using qRT-PCR for 25 classifier genes in Jurkat T cells,-,-,-,-,"ABCA1, ABCG1, AK4, ALDH8A1, ARRDC3, BZRAP1, CCNG2, CEBPB, etc.",-,"ABCA1: ATP Binding Cassette Subfamily A Member 1

ABCG1: ATP Binding Cassette Subfamily G Member 1

AK4: Adenylate Kinase 4

ALDH8A1: Aldehyde Dehydrogenase 8 Family Member A1

ARRDC3: Arrestin Domain Containing 3

BZRAP1: Benzodiazepine Receptor Associated Protein 1

CCNG2: Cyclin G2

CEBPB: CCAAT Enhancer Binding Protein Beta",-,Upregulation in protein metabolism and cholesterol biosynthesis/transport genes; changes in immune regulation and transcription,Active,-,-,-,-,-,-,-,-,-,-,-,"
1000 μM",-,-,Gene expression biomarker assay for immunotoxicity (Fluidigm qRT-PCR); ATPlite cell viability assay,"Jurkat cells exposed 6h to subcytotoxic concentrations, RNA isolated, qRT-PCR for gene markers; viability by ATPlite",Immunotoxicity,-,-,-,human,Jurkat T cells,cell line,"
1000 μM",Significant gene expression changes; protein metabolism and cholesterol biosynthesis/transport genes affected,-,-,-,-,-,"Protein metabolism, cholesterol biosynthesis/transport, immune regulation, stress response",Quantitative Real Time PCR (Fluidigm platform); ATPlite luminescence (ATP-based viability),blood,-,-,10.1002/jat.3079,-,-,-
106,Lit_review,Cypermethrin,Pyrethroid,"Molecular docking binding affinity to adaptive immune T-cell (CD4, CD8) and B-cell receptors (CD28, CD45)","
Cypermethrin ligand docking to human immune receptors (CD28, CD4, CD8, CD45)",-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,In silico molecular docking and toxicity prediction (ProTOX tool),Computational docking of cypermethrin to immune receptors; toxicity class prediction via ProTOX,Immunotoxicity prediction,-,-,-,human,-,-,-,Cypermethrin showed strong binding interaction especially with CD28 receptor; probable toxicity targets: AOFA and PGH1,-,"Immune cell receptor proteins (CD28, CD4, CD8, CD45); enzyme targets AOFA (Amine oxidase flavin-containing A), PGH1",Immune receptor proteins; enzymes involved in oxidative metabolism,T-cell co-stimulatory receptor (CD28); amine oxidase; prostaglandin synthase,Immune receptor family; flavin-containing amine oxidases; cyclooxygenases,"Immune regulation, oxidative enzymatic activity, inflammation",Computational molecular docking (Maestro 9.3); in silico rodent LD50 prediction (ProTOX tool),inmune cells,-,-,10.4103/pm.pm_62_17,-,-,-
107,Lit_review,Cypermethrin,Pyrethroid,"
Pesticide exposure effects on fish cell lines RTG-2 (rainbow trout gonadal cells) and RTL-W1 (rainbow trout liver cells)","Cytotoxicity endpoints by EROD enzymatic activity, neutral red (NR) uptake assay, β-Galactosidase activity, and FRAME Kenacid Blue protein (KBP) assay",-,-,-,-,-,-,-,Inhibition or induction of cytochrome P450 activity affecting xenobiotic metabolism and cell viability,"
Induction or inhibition of EROD (CYP1A) enzyme activity, lysosomal viability (neutral red), protein content changes",Inactive,-,-,-,-,-,-,-,-,-,-,-,"
18 mg/L ",-,-,"EROD assay, Neutral Red uptake assay, β-Gal assay, FRAME KBP assay",Enzymatic activity and cytotoxicity tests after 24 h exposure to cypermethrin in fish cells,In vitro cytotoxicity and enzyme activity measurement assay,-,-,-,trout,RTG-2 + RTL-W1,cell lines, up to 18 mg/L,"
No effect on EROD, β-Gal activity, and NR uptake was observed at tested concentrations",-,Cytochrome P450 family (implicated in EROD activity),-,-,-,"Xenobiotic metabolism, lysosomal integrity, protein content","
Fluorometric enzyme activity (EROD), spectroscopy (neutral red, KBP), β-Gal enzymatic fluorescence",liver + gonadal ,-,-,https://doi.org/10.1016/j.envpol.2004.11.001,-,-,-
108,Lit_review,Cypermethrin,Pyrethroid,"
Cypermethrin exposure on goat and dog spermatozoa","Cytotoxicity and motility parameters in spermatozoa measured via MTT (mitochondrial activity/viability), Neutral Red (lysosomal activity), and CASA (motility)","MTT, Neutral Red, and CASA","MTT (mitochondrial activity/viability), Neutral Red (lysosomal activity), and CASA (motility)",-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,MTT cytotoxicity assay; Neutral Red viability assay; Computer-assisted sperm analysis (CASA) for sperm motility,"In vitro exposure of spermatozoa to cypermethrin, with measurement of mitochondrial activity, lysosomal function, and motility parameters","
Toxicity and motility functional assay",-,1000,μg/μL,dog + goat ,Freshly collected spermatozoa,primary cells,"
Serial dilution from 166.67 μg/μL stock solution down to low μg/mL","
Significant cytotoxicity with dose-dependent decreases in viability; reduced sperm motility and hyperactivity parameters, especially in buck sperm",-,-,-,-,-,"Mitochondrial function, lysosomal integrity, sperm motility",MTT colorimetric assay (mitochondrial viability); Neutral Red spectrophotometric assay (lysosomal viability); CASA computerized motility analysis,spermatozoa,-,-,10.9775/kvfd.2016.16501,-,-,-
109,Lit_review,Cypermethrin,Pyrethroid,"Growth inhibition, cell biovolume change, and ultrastructural alterations assessed in the green microalga Selenastrum capricornutum","
Exposure of Selenastrum capricornutum microalgae to cypermethrin",-,-,-,-,-,-,-,-,"
Reduced algal population growth rate; increased cell size; ultrastructural damages including thylakoid and mitochondria disruption, lipid accumulation, and starch granule increase",Active,-,-,-,"for growth inhibition: 31.31 mg/L (24 h), 16.36 mg/L (48 h), 12.46 mg/L (72 h), 12.37 mg/L (96 h)",-,-,-,-,-,-,-,100 mg/L,-,-,Microalgal growth inhibition assay; electron microscopy ultrastructural analysis,Population growth and cell volume/count measurements over 96 h exposure; transmission electron microscopy of cellular ultrastructure,"
Ecotoxicological growth inhibition and morphological toxicity assay",-,-,-,"
Selenastrum capricornutum","
Wild-type microalgal cultures",-,3.12 - 100 mg/L (series of half-serial dilutions),"Dose-dependent growth inhibition, increased biovolume, ultrastructural damage (damaged chloroplasts, mitochondria, lipid accumulation)",-,Photosynthetic and metabolic organelles within algal cells,"Population counts (microscopy), cell volume measurement, transmission electron microscopy",-,-,"Photosynthesis, energy production, cell growth and division","Population counts (microscopy), cell volume measurement, transmission electron microscopy",microalgal cells,-,-,10.1590/0001-3765202120200233,-,-,-
110,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
111,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Hu et al. 2012; 22172556; 10.1016/j.tox.2011.11.019,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
112,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
113,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Wang et al. 2015; 26125603; 10.1016/j.etap.2015.06.008,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
114,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,LEL,-,-,-,-,-,-,-,-,-,LEL= 10000 nM,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,LEL= 10000 nM,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Hu et al. 2012; 22172556; 10.1016/j.tox.2011.11.019,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
115,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,LEL,-,-,-,-,-,-,-,-,-,LEL= 10000 nM,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,LEL= 10000 nM,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Wang et al. 2015; 26125603; 10.1016/j.etap.2015.06.008,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
116,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,LEL,-,-,-,-,-,-,-,-,-,LEL= 10000 nM,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,LEL= 10000 nM,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Hu et al. 2012; 22172556; 10.1016/j.tox.2011.11.019,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
117,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
118,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
119,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
120,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Sun et al. 2007; 16857237; 10.1016/j.chemosphere.2006.05.059,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
121,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kjeldsen et al. 2013; 23871939; 10.1016/j.taap.2013.06.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
122,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
123,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
124,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kjeldsen et al. 2013; 23871939; 10.1016/j.taap.2013.06.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
125,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,LEL,-,-,-,-,-,-,-,-,-,100 nM,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,100 nM,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
126,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
127,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
128,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
129,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
130,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,RIC20,-,-,-,-,-,-,-,-,-,RIC20 (nM)= 420000,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,RIC20 (nM)= 420000,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Hu et al. 2012; 22172556; 10.1016/j.tox.2011.11.019,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
131,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,RIC20,-,-,-,-,-,-,-,-,-,RIC20 (nM)=1640,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,RIC20 (nM)=1640,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
132,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Hu et al. 2012; 22172556; 10.1016/j.tox.2011.11.019,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
133,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kjeldsen et al. 2013; 23871939; 10.1016/j.taap.2013.06.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
134,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kjeldsen et al. 2013; 23871939; 10.1016/j.taap.2013.06.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
135,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
136,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Hu et al. 2012; 22172556; 10.1016/j.tox.2011.11.019,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
137,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Wang et al. 2015; 26125603; 10.1016/j.etap.2015.06.008,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
138,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kjeldsen et al. 2013; 23871939; 10.1016/j.taap.2013.06.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
139,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
140,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
141,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
142,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
143,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Hu et al. 2012; 22172556; 10.1016/j.tox.2011.11.019,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
144,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
145,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kjeldsen et al. 2013; 23871939; 10.1016/j.taap.2013.06.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
146,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
147,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kjeldsen et al. 2013; 23871939; 10.1016/j.taap.2013.06.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
148,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kjeldsen et al. 2013; 23871939; 10.1016/j.taap.2013.06.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
149,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Hu et al. 2012; 22172556; 10.1016/j.tox.2011.11.019,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
150,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Sun et al. 2007; 16857237; 10.1016/j.chemosphere.2006.05.059,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
151,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
152,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
153,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
154,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Hu et al. 2012; 22172556; 10.1016/j.tox.2011.11.019,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
155,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
156,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
157,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
158,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
159,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
160,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
161,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
162,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Wang et al. 2015; 26125603; 10.1016/j.etap.2015.06.008,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
163,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kjeldsen et al. 2013; 23871939; 10.1016/j.taap.2013.06.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
164,ICE,Cypermethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kjeldsen et al. 2013; 23871939; 10.1016/j.taap.2013.06.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
165,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kjeldsen et al. 2013; 23871939; 10.1016/j.taap.2013.06.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
166,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kjeldsen et al. 2013; 23871939; 10.1016/j.taap.2013.06.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
167,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Sun et al. 2007; 16857237; 10.1016/j.chemosphere.2006.05.059,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
168,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
169,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
170,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
171,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Du et al. 2010; 20410157; 10.1093/toxsci/kfq120,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
172,ICE,Cypermethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023998
173,BioStudies,Permethrin,Pyrethroid,wMFR and AEs on primary rat cortical neurons,Effects of permethrin exposure on mean firing rate (wMFR) and number of active electrodes (AEs) in primary rat cortical neuron networks on multi-well microelectrode arrays (mwMEA), and AEs on primary rat cortical neurons,"Postnatal day 0–1 (P0–P1) Long-Evans rat cortical neurons dissociated, plated on 12-well MEA plates (64 electrodes per well), cultured for DIV 14–22 before testing",Single concentration screening assay to detect neuroactive or neurotoxic effects of compounds on neuronal network firing and activity using mwMEA plates,-,-,-,-,Disruption/modulation of voltage-gated sodium channel (VGSC) gating in neurons (pyrethroid mode of action),Changes in network mean firing rate and number of active electrodes after 30 min exposure,Active,-,-,-,-,-,"
14% change in wMFR; 20% change in # active electrodes (AEs)",-,-,-,-,-,50 μM,"wMFR (spikes/min, weighted by number of active electrodes), percent of control","Multi-well MEA platform (Axion Biosystems/AxIS), EPA Integrated Systems Toxicology Division",Multi-well microelectrode array spontaneous network activity assay,"Recordings of spontaneous activity before and after deltamethrin application, quantifying changes in network spike rate and AEs",Neuronal network function/toxicity screen,-,50,mM,rat,Primary cortical neurons,monolayer on MEA,50 μM,Mean weighted firing rate increased by approximately 47% compared to baseline; number of active electrodes decreased by ~6.7%,No cytotoxicity at 50  μM,Voltage-gated sodium channels ,Neuronal ion channel,"
Sodium channel",-,"Neuronal excitability, action potential generation, synaptic transmission",Microelectrode array electrophysiology,brain ,-,3–7 replicates,https://doi.org/10.1016/j.neuro.2012.05.001,NT,-,-
174,BioStudies,Permethrin,Pyrethroid,wMFR and mwMEA in primary rat cortical neurons,Effect on spontaneous neuronal network activity measured by weighted mean firing rate (wMFR) in primary rat cortical neurons cultured on 48-well microelectrode arrays (mwMEA),wMFR and mwMEA in primary rat cortical neurons,Primary cortical neurons derived from postnatal day 0–1 Long-Evans rats cultured on 48-well mwMEA plates (~14 days in vitro). Single concentration neural activity assay assessing acute effect  (1 hour exposure) of permethrin on spontaneous neuronal firing rate using mwMEA system.,-,-,-,-,-,-,Change in firing rate as measured by wMFR in neuronal networks after 1 hour exposure,Inactive,-,-,-,-,-,"
±16.7% change in wMFR (hit threshold based on DMSO control ±2 SD)",-,-,-,-,-,"
40 μM",Weighted mean firing rate (wMFR) normalized to baseline,"EPA Integrated Systems Toxicology Division, Axion Biosystems mwMEA platform",Multi-well microelectrode array spontaneous activity assay,Measurement of spontaneous electrical activity in primary rat cortical neurons before and after compound treatment,"
Functional electrophysiology neurotoxicity screen",-,20,mM,rat,primary cortical neurons,dissociated on MEA,40 μM ,16.4% decrease in weighted mean firing rate (wMFR) compared to baseline; below hit threshold (threshold ±16.7%),No cytotoxicity observed,Voltage-gated sodium channels,Neuronal ion channel,"
Sodium channel",-,"Neuronal excitability, action potential modulation",Multi-electrode array extracellular electrophysiology,brain,-,at least n=2,10.1016/j.neuro.2014.06.012,NT,-,-
175,BioStudies,Permethrin,Pyrethroid,Effect on neural network development in rat cortical cultures as measured by 17 electrophysiological network parameters,"
Mean firing rate, mutual information, correlation, burst rate, # active electrodes, # actively bursting electrodes, and other network parameters",Effect on neural network development in rat cortical cultures,Screening for developmental neurotoxicity (DNT) via perturbation of neural network function using MEA; viability measured by Alamar Blue/LDH,-,-,-,-,-,Disruption of neural network development (general DNT context),"
Network development disruption; reduced neural activity",Active,-,-,-,"25,64 μM",-,-,-,-,-,-,-,30μM,Network activity values normalized to plate controls,"Frank et al., US EPA Integrated Systems Toxicology Division",Microelectrode array-based neural network formation assay,"Rat cortical cells cultured and exposed to permethrin, monitored for spontaneous activity, synchrony, and cell viability as network formed (12DIV)",Functional neurotoxicity screening,-,30,mM,rat,Primary cortical neurons (plus glia),primary mixed cells,"0.03μM, 0.1μM, 0.3μM, 1μM, 3μM, 10μM, 30μM",Permethrin perturbed several neural network parameters in a concentration-dependent manner,Cytotoxicity (Alamar Blue/LDH) measured at DIV12 for highest concentrations; network effects observed below cytotoxic concentrations,-,-,-,-,"Neural network development, synaptic function, neural coordination","Electrophysiology, metabolic activity, enzymatic lysis",brain,-,-,https://doi.org/10.1093/toxsci/kfx169,DNT,-,-
176,BioStudies,Permethrin,Pyrethroid,"Effect on spontaneous electrical activity and network formation parameters (spiking, bursting, synchronicity) in primary rat cortical neurons grown on MEAs","Mean firing rate, burst rate, number of active electrodes, number of actively bursting electrodes, percent of spikes in bursts, number of network spikes, percent of spikes in network spikes, Pearson’s correlation, mutual information","Effect on spontaneous electrical activity and network formation parameters (spiking, bursting, synchronicity) in primary rat cortical neurons grown on MEAs",Electrophysiological parameters describing the development of neural network function measured by microelectrode arrays over 12 days in vitro. Developmental neurotoxicity screening using the MEA-based network formation assay (NFA) in primary rat cortical cultures exposed continuously from 2h after plating through 12 DIV.,-,-,-,-,-,Disruption of voltage-gated sodium channels leading to altered neuronal network activity and developmental neurotoxicity,"Reduced firing rates, altered network bursting and synchrony indicative of disrupted neural network formation and function",Active,-,-,-,"11,8 μM (AUC)",-,-,-,-,-,-,-,20 μM,Data normalized relative to untreated control wells per plate,"Shafer et al., US EPA Integrated Systems Toxicology Division; Toxicological Sciences 2019",Neural Network Formation Assay (NFA) using multiwell microelectrode array (MEA) technology,"Primary rat cortical neurons plated on 48-well MEA plates, exposed to permethrin continuously from plating for 12 days, electrophysiological recording on DIV 5, 7, 9, and 12, viability assessed on DIV12",Functional developmental neurotoxicity assay measuring integrated neural network activity,-,20,mM,rat,Primary mixed cortical neuron culture,primary culture,Range from 0.03 μM to 20 μM in half-log increments,"Significant, concentration-dependent decrease in multiple parameters of network activity consistent with neurotoxicity; selective effects (network effect EC50 lower than viability EC50)",Network activity was disrupted at concentrations below those causing cytotoxicity in viability assays,Voltage-gated sodium channel (VGSC),Ion channel,Sodium channel,-,"Neural network formation and function, synaptic transmission, ion channel activity","Electrophysiological microelectrode array (MEA), metabolic viability assays (Alamar Blue, LDH)",brain,-,-,doi: 10.1093/toxsci/kfz052,DNT,-,-
177,BioStudies,Permethrin,Pyrethroid, Neural network development; identification of toxicological tipping points where network recovery fails.,"9 primary network activity parameters: mean firing rate (MFR), number of active electrodes (#AE), burst rate (BR), number of actively bursting electrodes (#ABE), percent of spikes in bursts (%SiB), number of network spikes (#NS), percent of spikes in network spikes (%SiNS), Pearson correlation (r), mutual information (MI)", Neural network development; identification of toxicological tipping points where network recovery fails.,"Parameters reflect spontaneous spiking, bursting, synchrony, and connectivity in developing networks recorded using MEAs.",-,-,-,-,-,network function disruption as an early key event for developmental neurotoxicity (DNT),Disruption of spontaneous neural network formation and function during early in vitro development,Active,-,-,-,-,-,-,-,-,-,-,-,30μM ,"Z-scored, plate-normalized fold-change vs. controls for each network paramete",US EPA Integrated Systems Toxicology Division,Microelectrode Array Neural Network Development Assay (mwMEA),Medium-throughput assay quantifying disruption of network development in primary rat cortical cultures by monitoring electrical activity over 12 days in vitro,"Functional, physiological neurotoxicity screening",-,-,-,rat,Primary mixed cortical neuron culture,primary culture,0.03–30μM; tipping point reported at 0.871μM (with 95% CI 0.64 to 1.288μM),"Clear, concentration-dependent disruption of network ontogeny; irreversible effect (“tipping point”) observed",Tipping point concentration (0.871μM) well below concentration for 50% reduction in viability (not cytotoxic at tipping point concentration),"nervous system function (primarily voltage-gated sodium channels, as known pyrethroid mechanism)",Voltage-gated sodium channel modulator,-,-,Neural network formation; developmental neurotoxicity screening,Microelectrode array (MEA) extracellular electrophysiology,brain,-,-,https://doi.org/10.1016/j.taap.2018.01.017,DNT,-,-
178,Lit_review,Permethrin,Pyrethroid,Cytotoxicity assays (cell viability),Pesticide cytotoxicity was evaluated by reduction of metabolic activity (via Alamar Blue/Resazurin-based assay). Multiple tissue-specific cultures were used to reflect different toxicodynamic responses.,-,-,-,-,-,-,-,-,-,Active,-,-,-,"metabolic activity: >1000 in thre cell lines; membrane integrity: >1000 in 
RTgutGC, 426.7 in RTgill‐W1, and 543.7 in RTL‐W1",-,-,-,-,-,-,-,1000 μM ,-,-,assays of metabolic activity (alamarBlue fluorescent dye) and membrane integrity (CFDA‐AM fluorescent dye),"The exposure medium was discarded, and the alamarBlue and (CFDA‐AM) cytotoxicity assays were conducted immediately to assess metabolic activity and membrane integrity, respectively. Briefly, the cells were rinsed in 100μL of phosphate‐buffered saline (PBS) following which alamarBlue (5% v/v in PBS)+CFDA‐AM dye was added to the wells, and the cells were incubated for 30min. Next, fluorescence was read at 530nm/595nm for alamarBlue and 493nm/541nm for CFDA‐AM using a Synergy HT Gen5 microplate reader (BioTek).",Viability,-,200,Mm,Trout," RTgill-W1, RTL-W1, RTgutGC ",cell line ,0.01 – 1000 µM (x24h),"In 24-h exposures across eight concentrations (spanning ~3.5 orders of magnitude) in rainbow trout gill (RTgill-W1), liver (RTL-W1), and gut (RTgutGC) cell lines, cytotoxicity was measured by metabolic activity (alamarBlue) and membrane integrity (CFDA-AM). Permethrin produced concentration-dependent effects only on membrane integrity in gill and liver cells; it did not elicit a metabolic-activity response in those cells, and it showed no cytotoxicity in the gut cell line under the tested conditions. Notably, mass-balance modeling predicted that <3% of nominal permethrin remained in the exposure medium (reflecting high hydrophobicity), and when EC50s were expressed using these predicted concentrations, permethrin ranked among the most potent compounds (EC50 ≲ ~1 μM) in gill cells, with a similar potency ranking pattern in liver cells.",-,-,-,-,-,-,Fluorescence,"gill, gut, and liver",-,-,https://doi.org/10.1002/etc.5808,-,-,-
179,Lit_review,Permethrin,Pyrethroid,Cytokinesis-block micronucleus cytome (CBMN cyt) assay ,"Genotoxicity was evaluated using the cytokinesis-block micronucleus cytome (CBMN cyt) assay by measuring the frequency of micronuclei (MN), nuclear division index (NDI), formation of nucleoplasmic bridges (NPB) and nuclear buds (NBUD), as well as apoptotic and necrotic cells",-,-,-,-,-,-,-,-,"DNA damage, chromosomal instability, cytostasis (cell cycle effects), and cytotoxicity ",Active,-,-,-,-,-,-,-,-,-,-,-,10/0.14 μg/ml of permethrin/allethrin mixture ,-,-,CBMN cyt assay,"The Cytokinesis-Block Micronucleus Cytome (CBMN cyt) assay is a comprehensive cytogenetic technique that measures DNA damage, cytostasis, and cytotoxicity in cells, specifically analyzing once-divided binucleated cells. It evaluates several biomarkers of genotoxicity including micronuclei (MN), nucleoplasmic bridges (NPBs), and nuclear buds (NBUDs), as well as cellular effects such as the nuclear division index (NDI) and apoptosis/necrosis.",Viability,-,-,-,human ,PBL,peripheral blood lymphocytes ,"permethrin/allethrin mixture:  1/0.01, 5/0.07, and 10/0.14 μg/ml  for 24 or 36 h.","The highest concentration (10/0.14 μg/ml) of permethrin/allethrin mixture significantly increased MN frequency and percent apoptotic cells after incubations for 24 or 36 h. The NDI was markedly decreased in response to treatment with 5/0.07 or 10/0.14 μg/ml permethrin/allethrin for both 24 and 36 h. Exposure to the permethrin/allethrin mixture did not significantly alter formation of NBUD, NPB, or percent necrotic cells. The MN frequency was significantly correlated with the number of apoptotic and necrotic cells but inversely correlated with NDI. Data demonstrated that a mixture of permethrin and allethrin induced concentration- and time-dependent cytotoxic and genotoxic damage to human PBL in vitro. ",-,-,-,-,-,-,Microscopy,blood,-,-,10.1080/15287394.2015.956025,-,-,-
180,Lit_review,Permethrin,Pyrethroid,QSAR and SSD models to predict aquatic toxicity and species sensitivity of pyrethroid,"The QSAR models, described by the formula 48 h-EC50 or 96 h-LC50 = x + y * log Kow, were validated for predicting 48 h-EC50 values for acute Daphnia toxicity and 96 h-LC50 values for acute fish toxicity, meeting criteria of n ≥10, r2 ≥0.7, and Q2 >0.5. ",-,-,-,-,-,-,-,-,-,-,-,-,-,Predicted 48 h-EC50 values: 3.95 × 10-5 mg/L (permethrin). Predicted 96 h-EC50 values:  3.89 × 10-5 mg/L (permethrin). ,-,-,-,-,-,-,-,-,-,-,QSAR and SSD models, In this study QSAR and SSD models for six pyrethroid and four organophosphate compounds using QSAR Toolbox and SSD Toolbox,Toxicity prediction models,-,-,-,-,-,-,-,"Predicted 48 h-EC50 values: 3.95 × 10-5 mg/L (permethrin). Predicted 96 h-EC50 values:  3.89 × 10-5 mg/L (permethrin). These values show a good agreement with experimental data. HC05 values, indicating hazardous concentrations for 5% of species, range from 0.029 to 0.061 µg/L for pyrethroids. These values aid in establishing environmental quality standards (EQS). Compared to existing EQS, HC05 values for pyrethroids were less conservative, while those for organophosphates were comparable.",-,-,-,-,-,-,Computational and stadistical methods,-,-,-,10.1080/1062936X.2024.2389818,-,-,-
181,Lit_review,Permethrin,Pyrethroid,"Computational simulations: homology modeling, molecular docking, molecular dynamic simulations (MDs). Bioassay: Zebrafish blood exposure experiment","Homology modeling is a computational technique used to predict the three-dimensional structure of a protein by comparing its amino acid sequence to known structures, enabling insights into protein function and interactions. Molecular docking simulates and predicts how small molecules, like drugs, bind to a target protein by exploring possible orientations and binding affinities to identify the most favorable interactions. Molecular dynamics simulations extend this by modeling the physical movements of atoms and molecules over time, providing detailed information about the stability, flexibility, and dynamics of biomolecular complexes in realistic environments. Complementing these computational approaches, the zebrafish blood exposure bioassay involves experimentally exposing zebrafish to chemicals to assess biological effects on their circulatory system.",-,-,-,,-,-,-,Binding to estrogen receptors,Reproductive toxicity,-,-,-,-,-,-,-,-,-,-,-,-,-,-,-,"homology modeling, molecular docking, molecular dynamic simulations (MDs) ","To investigate the reproductive toxicity of pyrethroids, homology modeling, molecular docking, molecular dynamic simulations (MDs) were conducted to explore the interaction between pyrethroids and ERα from atomic scale. The human ERα (2YJA) was selected as a template protein for homology modeling. Then eight typical pyrethroids and positive control estradiol were docked to the modeled protein. ",Reproductive toxicity prediction models,-,-,-,-,-,-,-,"Molecular dynamic simulations (MDs) showed that the complex formed by permethrin with ERα had a lower RMSD value and binding free energies compared to bifenthrin. Based on these results from microscopic dimension, exposure experiments were implemented to validate the primary conclusions. VTG concentrations in male zebrafish’s blood were significantly higher under permethrin exposure than bifenthrin, suggesting a stronger estrogenic activity and binding propensity, and consequently, higher reproductive toxicity. ",-,Estrogen receptors (ER) ,-,-,-,Endocrine function,Computational modeling + ,zebrafish´s blood,-,-,10.1016/j.colsurfb.2022.112565,-,-,-
182,Lit_review,Permethrin,Pyrethroid,Metabolomic analysis by gas chromatography-mass spectrometry,"We have used a mass spectrometry-based untargeted metabolomics approach to characterize for the first time the changes in the metabolome of the B50 cell line, an immortalised rat neuronal cell line, following acute exposure to two known neurotoxic chemicals that are common environmental contaminants; the pyrethroid insecticide permethrin and the organophosphate insecticide malathion. ",-,-,-,-,-,-,-,-,Metabolites alterations,Active,-,-,-,-,-,-,-,-,-,-,-,0.51 mM,-,-, Mass spectrometry-based untargeted metabolomics,Comprehensive analytical approach that aims to globally profile and characterize all detectable metabolites within a biological sample without prior knowledge of what those metabolites might be.,Metabolism ,-,-,-,rat,B50,cell line ," 6 and 24 hours of 200 μg/ml permethrin, equivalent to 0.51 mM for permethrin","By considering the major fold changes in abundance (>2.0 or <0.5 from control) across themetabolites altered by chemical exposure, we were able to elucidate important cellular events associated with toxic exposure including disrupted energy metabolism and attempted protective mechanisms from excitotoxicity. Permethrin exposure from 0 to 24 hours resulted in an 8.5% increase in growth rate. Comparing the control to exposure groups at each time point, the number of viable cells at 6 hours was similar for all groups; only the permethrin-exposed group showed a significant 18.5% decrease from control (P = 0.03846). At 24 hours the effect of the chemical exposure on cell growth and survival became apparent, as both insecticides showed a significant decrease in viable cells from control; permethrin exposure resulted in 37.0% fewer cells than the control at the same time point (P = 0.00021). Permethrin exposure resulted in a predominantly fatty acid-based response.",-,-,-,-,-,Metabolism,Mass-spectrometry,brain,-,4 replicates/group,10.1002/jat.3498,-,-,-
183,Lit_review,Permethrin,Pyrethroid,Cytotoxicity assessed by cell viability; protective efficacy against pyrethroid cytotoxicity,MTT cytotoxicity assay measuring cell viability after exposure to insecticides including permethrin; enzymatic assays for P450 detoxification activity on Sf9 insect cells engineered to express mosquito P450 enzymes CYP6P7 or CYP6AA3. They were used to test detoxification capacity.,-,-,-,-,"CYP6P7, CYP6AA3",-,Cytochrome P450 monooxygenases CYP6P7 and CYP6AA3,Detoxification of permethrin by cytochrome P450 enzymes reduces cytotoxicity; inhibition of P450 increases cytotoxicity,"Cytoprotection from cytotoxicity, enzymatic metabolism of permethrin",Active,-,-,-,-,-,-,-,-,-,-,-,500 µM,Cell viability percentage,-,"MTT cytotoxicity assay, in vitro enzymatic reconstitution assay",Measurement of cytotoxicity and detoxification enzyme activity against permethrin in Sf9 insect cells,"viability, detoxification capability assessment",-,-,-,Spodoptera frugiperda,Sf9 ,cell line ,0.1-500 µM ,"Increased cell viability in CYP6P7 and CYP6AA3 expressing cells, indicating detoxification; decreased viability in parental cells exposed to permethrin",-,Cytochrome P450 enzymes,Enzymes,Monooxygenases,cytotoxicity,"Xenobiotic metabolism, detoxification",Colorimetric MTT assay,insect cells,-,-,https://pubmed.ncbi.nlm.nih.gov/22041748/,-,-,-
184,Lit_review,Permethrin,Pyrethroid,WST-test and total ATP measure,"The total ATP assay measures cell viability by quantifying the amount of adenosine triphosphate (ATP), a marker of metabolically active living cells. The WST test (Water-soluble Tetrazolium salt assay) is a colorimetric assay to assess cell viability and proliferation. It uses tetrazolium salts (e.g., WST-1 or WST-8) that are reduced by mitochondrial dehydrogenases in viable cells to produce a water-soluble formazan dye. The amount of dye produced correlates with the number of metabolically active cells and is quantified by measuring absorbance using a spectrophotometer. ",-,-,-,-,-,-,-,-,cytotoxicity (low total ATP and mitocondrial metabolic activity),Active,-,-,-,-,-,-,-,-,-,-,-,100μM,-,-,Total ATP and WST-test,"The total ATP assay measures cell viability by quantifying the amount of adenosine triphosphate (ATP), a marker of metabolically active living cells. It utilizes the bioluminescent reaction catalyzed by the enzyme luciferase in the presence of ATP and luciferin, producing light proportional to ATP concentration. As ATP is rapidly depleted in dead or dying cells, the luminescent signal directly correlates with the number of viable cells. The WST test (Water-soluble Tetrazolium salt assay) is a colorimetric assay to assess cell viability and proliferation. It uses tetrazolium salts (e.g., WST-1 or WST-8) that are reduced by mitochondrial dehydrogenases in viable cells to produce a water-soluble formazan dye. The amount of dye produced correlates with the number of metabolically active cells and is quantified by measuring absorbance using a spectrophotometer.",viability ,-,-,-,human ,SH-SY5Y,cell line ,0.1-100μM,"There was induction of enzyme activities with WST-1 test with all pyrethroid compounds studied at low concentrations. With the ATP assay, exposure to 0.1-100μM of natural pyrethrin, as well as of permethrin and cypermethrin showed dose-dependent cytotoxicity. The most toxic pyrethroid was cypermethrin followed by permethrin and natural pyrethrin.",-,mitochondrial metabolic enzymes,-,-,cytotoxicity,cell death,"Luminescence (total ATP), photometry (WST-test), microscopy (morphological changes)",brain,-,-,10.1016/j.etap.2003.11.005,-,-,-
185,Lit_review,Permethrin,Pyrethroid,WST-test and total ATP measure,"The proliferation of the breast cancer cell line, MCF7, was studied after a 7-day exposure to various concentrations of pyrethrin, permethrin and cypermethrin. The effects of oestradiol and the combined effects of oestradiol (0.10 nM) and pyrethroids (0.1-100 microM) on MCF7 cell proliferation were also evaluated. The total ATP assay measures cell viability by quantifying the amount of adenosine triphosphate (ATP), a marker of metabolically active living cells. The WST test (Water-soluble Tetrazolium salt assay) is a colorimetric assay to assess cell viability and proliferation. It uses tetrazolium salts (e.g., WST-1 or WST-8) that are reduced by mitochondrial dehydrogenases in viable cells to produce a water-soluble formazan dye. The amount of dye produced correlates with the number of metabolically active cells and is quantified by measuring absorbance using a spectrophotometer. ",-,-,-,-,-,-,-,-,cytotoxicity (low total ATP and mitocondrial metabolic activity),Active,-,-,-,-,-,-,-,-,-,-,-,100μM,-,-,Total ATP and WST-test,"The total ATP assay measures cell viability by quantifying the amount of adenosine triphosphate (ATP), a marker of metabolically active living cells. It utilizes the bioluminescent reaction catalyzed by the enzyme luciferase in the presence of ATP and luciferin, producing light proportional to ATP concentration. As ATP is rapidly depleted in dead or dying cells, the luminescent signal directly correlates with the number of viable cells. The WST test (Water-soluble Tetrazolium salt assay) is a colorimetric assay to assess cell viability and proliferation. It uses tetrazolium salts (e.g., WST-1 or WST-8) that are reduced by mitochondrial dehydrogenases in viable cells to produce a water-soluble formazan dye. The amount of dye produced correlates with the number of metabolically active cells and is quantified by measuring absorbance using a spectrophotometer.",viability ,-,-,-,human ,MCF7,cell line ,0.1-100μM,"n the ATP test, low concentrations (0.1-1 microM) of pyrethroids in co-exposure with oestradiol caused a clear statistically significant increase in the proliferation of MCF7 cells. This was evident when compared to the proliferative effect caused by 0.1 nM oestradiol alone. High concentrations were cytotoxic, and the greatest cell toxicity was that of cypermethrin, which has a cyano group in its molecular structure.",-,mitochondrial metabolic enzymes,-,-,cytotoxicity,cell proliferation and toxicity,"Luminescence (total ATP), photometry (WST-test)",breast ,-,-,10.1177/026119290403200410,-,-,-
186,Lit_review,Permethrin,Pyrethroid,Genotixicity and chromosomal damage with the cytokinesis-block method to assess micronulie formation after exposure to pyrethroids,"The cytokinesis-block method with 6 μg/ml cytochalasin B (Cyt-B) is a widely used technique in the cytokinesis-block micronucleus (CBMN) assay to assess chromosomal damage and genotoxicity. Cytochalasin B is a drug that inhibits actin polymerization, specifically blocking the formation of the contractile ring required for cytokinesis (the final step of cell division where the cytoplasm divides). By adding Cyt-B to cultured cells at a concentration of about 6 μg/ml, cytokinesis is prevented while nuclear division proceeds normally, resulting in the accumulation of binucleated cells, i.e., cells with two nuclei.",-,,-,-,-,-,-,-,micronucleus formation (MN) and cytotoxicity,Inactive,-,-,-,-,-,-,-,-,-,-,-,200  μg/mL,-,-,cytokinesis-block micronucleus (CBMN) assay,"It is a well-established cytogenetic assay that detects chromosomal damage by scoring micronuclei in binucleated cells, providing sensitive measurement of genetic damage caused by chemical agents such as insecticides in human lymphocyte cultures",viability ,-,-,-,human ,whole blood and lymfocytes,peripheral blood lymphocytes ,10-200  μg/mL,"At the concentration ranges tested, all the five pyrethroids induced clear dose dependent cytotoxic effects, fenpropathrin being the most toxic. Nuclear division index (NDI) and the newly introduced index of cytotoxicity, the cytokinesis block proliferation index (CBPI), reflected the dose dependency more accurately than the percentage of binucleated cells did.Permethrin gave mostly negative results, although it increased the MN frequency in WB cultures of one donor when 6 μg/ml Cyt-B was used.",-,-,-,-,cytotoxicity,cell cycle/proliferation,Fluorescence,blood,-,-, 10.1016/0165-1218(95)90007-1,-,-,-
187,Lit_review,Permethrin,Pyrethroid,Colony Forming Ability (CFA) assay,"in vitro technique to assess the long-term survival, proliferation, and cytotoxic effects of chemical treatments on cells. The assay measures the ability of a single viable cell to undergo unlimited division and form a colony consisting of at least 50 cells. This ability reflects the reproductive viability and proliferative capacity of the cells following exposure to a test compound.",-,,-,-,-,-,-,-,cell cycle arrest,Active,-,-,-,-,-,-,-,-,-,-,-,100 mg/ml,-,-,colony forming ability (CFA) assay + cell cycle analysis by flow cytometry + microscopic evaluation of the mitotic index.,"CFA assay is a widely used in vitro technique to assess the long-term survival, proliferation, and cytotoxic effects of chemical treatments on cells. The assay measures the ability of a single viable cell to undergo unlimited division and form a colony consisting of at least 50 cells. This ability reflects the reproductive viability and proliferative capacity of the cells following exposure to a test compound.",viability ,-,-,-,hamster,V79,cell line ,3.1–100 mg/ml,"The colony forming ability (CFA) resulted in distinct differences of the cytotoxic effect of the tested pyrethroids, whereby permethrin was found to be most toxic. With the exception of fenvalerate all tested pyrethroids gave rise to inhibition of cell cycle progression as shown by G2/M-arrest of synchronized V79 cells by flow cytometry as well as by the increase of the mitotic index as evaluated by light microscopy. ",-,-,-,-,cytotoxicity,cell cycle,Fllow-cytometry and microscopy,lung,-,-,https://doi.org/10.1016/S0378-4274(99)00034-X,-,-,-
188,Lit_review,Permethrin,Pyrethroid,MTT and LDH release assays,MTT assay to assess cell viability/cytotoxicity and LDH release assay for membrane integrity. Confocal and light microscopy used for morphological assessment.,-,,-,-,-,-,-,-,cytotoxicity ,Active,-,-,-,105.3 ng/mL (MTT assay),-,-,-,-,-,-,-,200 ng/mL ,-,-,"MTT assay, LDH release, EROD activity (CYP1A), microscopy",MTT: Mitochondrial function and cell viability. LDH: Membrane damage/cell lysis during apoptosis/necrosis. EROD: Measurement of CYP1A induction indicating biotransformation/phase I metabolic capacity. Microscopy: Morphological characterization of cellular/subcellular alterations,"viability, cytotoxicity, and enzyme induction",-,10,mg/mL,trout,RTG-2,cell line ," 6.25, 12.5, 25, 50, 100, 200 ng/mL for toxicity assays; IC50 for microscopy/EROD (105.3 ng/mL)","IC50 (MTT, permethrin): 105.3 ng/mL (least cytotoxic among tested pyrethroids). Morphological effects (microscopy): Condensed/pyknotic nuclei, fragmented morphology, cell shrinkage, cytoplasmic vacuoles, pleomorphism, hydropic degeneration. LDH release: Increased, non-dose dependent, max 78.13%. EROD induction (CYP1A): 5.01-fold increase at IC50 compared to controls",-,-,-,-,-,-,Colorimetric (MTT/LDH); Fluorometric (EROD); Microscopy,Gonadal/mixed testis-ovary cells,-,-,https://doi.org/10.1080/15569543.2017.1366922,-,-,-
189,Lit_review,Permethrin,Pyrethroid,"MTT assay, Neutral Red Uptake (NRU) assay, Nile Red (lipid) staining, Perilipin immunofluorescence, Western blot","Adipogenic differentiation, lipid accumulation, perilipin expression, adipogenic marker expression, autophagy regulation effects of permethrin in mesenchymal stem cells (MSCs)",-,MTT: Cell metabolic activity and viability. NRU: Lysosomal integrity/viability. Nile Red: Intracellular lipid droplets. Western blot: Quantified adipogenic and autophagic proteins,-,-,-,-,-,-,dipogenic differentiation +autphagy,Active,-,-,-,-,-,-,-,-,-,-,-,100 μM,-,-,"MTT, NRU, Nile Red staining, Perilipin immunofluorescence, Western blot for marker proteins","Various cellular and biochemical endpoints to assess adipogenic commitment, lipid accumulation, autophagy modulation","viability, lineage commitment, autophagy (protein) marker analysis",-,-,-,mice,Primary mouse bone marrow mesenchymal stem cells (MSCs),primary cells,"1, 10, 100 μM tested; 100 μM used for mechanistic studies","No cytotoxicity at tested doses (MTT, NRU). Dose-dependent increase in adipogenic commitment: lipid staining, perilipin, and marker proteins (PPARγ, C/EBPα, FABP4). Autophagy inhibition: increased LC3II and p62 proteins.",-,-,-,-,-,"Adipogenic differentiation, autophagy regulation","Colorimetric (MTT, NRU), Fluorescence (Nile Red, Perilipin), Immunoblotting (Western blot)",bone marrow,-,-,https://doi.org/10.1016/j.pestbp.2023.105566,-,-,-
190,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
191,ICE,Permethrin,Pyrethroid,AR Binding,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding,,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
192,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
193,ICE,Permethrin,Pyrethroid,AR Binding,Ki,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding,,-,-,-,-,-,-,-,-,ki=330000 nM,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
194,ICE,Permethrin,Pyrethroid,AR Binding,RBA,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding,,-,-,-,-,-,-,-,-,RBA (Relative Binding Affinity)= 1.5E-5,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
195,ICE,Permethrin,Pyrethroid,AR Binding,Receptor binding,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding,,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
196,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kojima et al. 2004; 15064155; 10.1289/ehp.6649,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
197,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kojima et al. 2004; 15064155; 10.1289/ehp.6649,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
198,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
199,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
200,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
201,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
202,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
203,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
204,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Sun et al. 2007; 16857237; 10.1016/j.chemosphere.2006.05.059,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
205,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Sun et al. 2007; 16857237; 10.1016/j.chemosphere.2006.05.059,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
206,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Xu et al. 2008; 17980950; 10.1016/j.tox.2007.09.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
207,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Sun et al. 2007; 16857237; 10.1016/j.chemosphere.2006.05.059,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
208,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kojima et al. 2004; 15064155; 10.1289/ehp.6649,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
209,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
210,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,AC50/EC50/IC50,-,-,-,-,-,-,-,-,-,Active,-,-,-,730000 nM,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,AC50=730000 nM,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
211,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
212,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
213,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
214,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
215,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
216,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
217,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
218,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
219,ICE,Permethrin,Pyrethroid,AR Binding and Transactivation,AR agonist potency,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Binding and Transactivation,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
220,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
221,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Sun et al. 2007; 16857237; 10.1016/j.chemosphere.2006.05.059,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
222,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
223,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
224,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
225,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
226,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Sun et al. 2007; 16857237; 10.1016/j.chemosphere.2006.05.059,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
227,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kojima et al. 2004; 15064155; 10.1289/ehp.6649,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
228,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,LEL,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,LEL=30000 nM,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
229,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
230,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
231,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Sun et al. 2007; 16857237; 10.1016/j.chemosphere.2006.05.059,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
232,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kojima et al. 2004; 15064155; 10.1289/ehp.6649,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
233,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
234,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
235,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
236,ICE,Permethrin,Pyrethroid,AR Transactivation-Agonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Agonist,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Sun et al. 2007; 16857237; 10.1016/j.chemosphere.2006.05.059,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
237,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,IC20,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,IC20=51730 Nm,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
238,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,AC50/EC50/IC50,-,-,-,-,-,-,-,-,-,Active,-,-,-, 56800 nM,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,AC50= 56800 nM,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Xu et al. 2008; 17980950; 10.1016/j.tox.2007.09.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
239,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,RIC20,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,RIC20=430000 nM,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Sun et al. 2007; 16857237; 10.1016/j.chemosphere.2006.05.059,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
240,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,RIC20,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,RIC20=1880 nM,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
241,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
242,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
243,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
244,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
245,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
246,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
247,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
248,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kojima et al. 2004; 15064155; 10.1289/ehp.6649,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
249,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
250,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kojima et al. 2004; 15064155; 10.1289/ehp.6649,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
251,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Xu et al. 2008; 17980950; 10.1016/j.tox.2007.09.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
252,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Sun et al. 2007; 16857237; 10.1016/j.chemosphere.2006.05.059,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
253,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
254,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Call,-,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Inactive,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
255,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,LEL,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,LEL=10000 nM,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Xu et al. 2008; 17980950; 10.1016/j.tox.2007.09.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
256,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,LEL,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,LEL=100000 nM,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Sun et al. 2007; 16857237; 10.1016/j.chemosphere.2006.05.059,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
257,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,LEL,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,LEL=158000 nM,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
258,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,LEL,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,LEL=20000 nM,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
259,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,LEL,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,LEL=10000 nM,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Zhang et al. 2008; 18586453; 10.1016/j.reprotox.2008.05.054,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
260,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,LEL,-,-,-,-,-,-,-,-,-,Active,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,LEL=1000 nM,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
261,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
262,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kojima et al. 2004; 15064155; 10.1289/ehp.6649,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
263,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
264,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Sun et al. 2007; 16857237; 10.1016/j.chemosphere.2006.05.059,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
265,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
266,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
267,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Xu et al. 2008; 17980950; 10.1016/j.tox.2007.09.028,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
268,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
269,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kojima et al. 2004; 15064155; 10.1289/ehp.6649,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
270,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Negative,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347|Kim et al. 2006; 16621434; 10.1016/j.tiv.2006.03.003,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
271,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
272,ICE,Permethrin,Pyrethroid,AR Transactivation-Antagonist,Transcriptional change,-,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,-,-,-,-,AR Transactivation-Antagonist,,-,-,-,-,-,-,-,-,Decrease,-,-,-,-,-,-,-,-,-,-,https://doi.org/10.22427/NTP-DATA-DTXSID8022292,-,Kleinstreuer et al. 2016; 27933809; 10.1021/acs.chemrestox.6b00347,https://comptox.epa.gov/dashboard/chemical/details/DTXSID8022292
